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Abstract
Drug resistance is an increasing global problem, with very few novel compounds in develop-
ment, and transcription is a potent target for novel antibiotics. In this work, we set out to search
for novel compounds inhibiting RNA polymerase (RNAP) and to investigate their mode of ac-
tion, in collaboration with a university-based bio-tech company, DemurisTM. DemurisTM lab
screened a vast collection of Actinomycete strains, and identified strains that produced com-
pounds potentially targeting transcription. The purified compounds were then analysed by us
in vitro. Hundreds of compound were tested throughout this project. Most of the compounds
were identified as known relatives of Rifampicin, a widely used antibiotic that targets bacte-
rial RNAP. Some compounds, however, were identified as distinct molecules with potentially
interesting modes of actions, and were chosen for further characterization.
We found that compound DEM31376, later identified as antibiotic Madurastatin C1, inhib-
ited transcription initiation. However, a secondary metabolite, GE23077, was found to be
co-produced and co-purified with it. GE23077 is known to inhibit transcription by unknown
mechanism. We showed that the mixture (likely GE23077) inhibits binding of the initiating
nucleotide in the “i” site of the RNAP active centre.
DEM10430 was identified as the sequence dependent DNA intercalator Echinomycin. It pre-
vents translocation of RNAP. We found that DEM10430 does not inhibit transcription initiation
but blocks translocation of RNAP during elongation of transcription 1 bp upstream of its bind-
ing site.
DEM30355B1 is a novel derivative of antibiotic Kanglemycin A that belongs to the Ansamicyn
family, and which spontaneously degrades into a secondary form, DEM30355/B2. We showed
that both forms inhibit transcription initiation by blocking synthesis of RNA longer than 4
nucleotides, similar to Rifampicin. Interestingly, however, DEM30355B1 displayed activity
against Rifampicin-resistant RNAPs, suggesting its potential clinical usefulness.
Our study suggests that looking for new antibiotics targeting transcription is still promising.
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Chapter 1
Introduction
Transcription is a central process in the expression of genetic information and is performed by
DNA-dependent RNA polymerase (RNAP). RNAP is one of the most primordial enzymes on
the planet and is exceptionally conserved in evolution from bacteria to humans. Although there
are many structural differences between the RNAPs from the three domains of life (archaea,
bacteria and eukaryotes), the basic mechanism of catalysis is conserved throughout all domains
of life. The bacterial RNAP is composed, for example, of less subunits compared to the eukary-
otic and archaea counterparts, and therefore is an excellent model system for understanding the
basic principles of all cellular RNAPs (Werner and Grohmann, 2011).
RNAP uses nucleotide nucleotide triphosphates (NTPs) as substrates to synthesize an RNA se-
quence complementary to the DNA template. Three conserved aspartate residues within the
catalytic center coordinate the magnesium ion required for the catalysis.
1.1 Structure and Function of RNA Polymerase
The bacterial RNAP core-enzyme is composed of five subunits (2α, β’, β and ω) with a total
molecular mass of approximately 400 kDa. The core-enzyme bound by a sigma factor (σ) is
called holo-enzyme. The core enzyme by itself is able to transcribe the DNA, however binding
of the σ factor is required in order for the RNAP to bind to a promoter sequence and initiate
transcription.
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The first X-ray crystal structure of RNAP was obtained in 1999 using RNAP isolated from
Thermus aquaticus (Taq) (Zhang et al., 1999). Taq core enzyme shows a characteristic crab-
claw shape, with a deep channel separating the jaws of the claw. Further crystal structures
of RNAPs from reveal other organisms shown that both prokaryotic and eukaryotic RNAPs
have a similar shape, and, most importantly, that their active centres are essentially comparable
(Vassylyev et al., 2007).
1.1.1 Basic overview of RNAP
The overall structure of RNAP is formed, as mentioned, by five subunits. β’ together with the β
subunit form the largest part of the polymerase. They contain the active center responsible for
catalysis, and are responsible for non-sequence-specific interaction with the DNA and nascent
RNA. The 2α subunits are responsible for the assembling of RNAP, and for interaction with pro-
moter DNA and are determinant for interactions with different regulatory factors. The smallest
subunit ω facilitates the association of the σ factor with the core-enzyme. The bacterial RNAP
is composed of both fixed and mobile elements located within the two α subunit N-terminal
domains and the β and β’ subunits. These elements have four main functions: they serve as a
scaffold to hold the three conserved aspartate residues in the active site for catalysis; they form
the cleft that accommodates and positions the RNA:DNA hybrid in the active centre; they form
the secondary channel through which the nucleoside triphosphate (NTP) substrates enter, and
they also create the attachment site for the σ factor (Borukhov and Nudler, 2008).
The mobile elements are divided into two groups, those that participate in catalysis and RNAP
movement along the DNA, and those that are responsible for different other actions including
promoter binding. The mobile elements involved in catalysis include two β lobes which are
responsible for accommodation of the non-template DNA in the transcription bubble and re-
lease of both DNA and RNA upon termination (Fig.1.1). The β’ rudder, β’ lid, β’ zipper, β’
N-terminal Zn finger and β flap assist in positioning the DNA, RNA and DNA:RNA hybrid
within the enzyme and are also required for recognition of the σ factor (Fig.1.1). The mobile
elements not involved in catalysis include the σ factor and α subunit C-terminal domain, both
of which are involved in promoter recognition and binding (Kuznedelov et al., 2002; Murakami
CHAPTER 1. INTRODUCTION 3
et al., 2002; Naryshkina et al., 2006; Vassylyev et al., 2002).
β’ Secondary 
channel
β’ Trigger loop
Active 
center 
β’ Bridge     
helix 
β Lobes
β’ Clamp  β’ Rudder 
β’ lid  
β’ zipper  
β’ Zn2+ 
finger
β Flap  
α1,2 CTD
Figure 1.1: Structural overview of RNAP. Schematic representation of Thermus thermophilus
core-RNAP structure with mobile and fixed elements labelled (see text). Modified from
(Borukhov and Nudler, 2008)
.
As mentioned, the RNAP synthesizes an RNA strand from a DNA template, by transferring the
nucleotidyl moiety from the NTP substrate to the hydroxyl at the 3’ terminus of the nascent
transcript. Reaction is catalysed in the active centre (Fig.1.2) which is buried 30-40 Å away
from the surface. The active center is positioned on the back wall of the β’ subunit and three
main aspartate residues within the NADFDGD motif (Asp 739, 741, and 743, in E. coli) chelate
the first Mg2+ ion (Mg I) required for the catalysis. The second Mg2+ ion (Mg II) is brought
into the active centre in an ad hoc manner by the substrates and is only weakly bound to the
active center (Sosunov et al., 2003). The three main aspartate residues are conserved in all
RNAPs and any substitution abolishes the catalytic activity (Sosunov et al., 2005; Gross et al.,
1996).
The catalysic reaction of the RNAP enzyme is performed by two elements, the β’F(bridge)-helix
(BH) and β’G(trigger)-loop (TL), which play a crucial role in binding of the incoming NTP and
translocation of the RNAP nucleotide incorporation. The trigger loop has been shown to exist
either a "folded" or an "un-folded" conformation. In the folded (closed) conformation, the TL
blocks the secondary channel and correctly positions the incoming NTP in the active center. In
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Figure 1.2: Structure of RNAP active centre of Thermus thermophilus. Red: substrate NTP,
gold: template DNA, purple: Mg2+ ions, green: nascent RNA. All the residues involved in the
coordination of the Mg2+ ions and the orientation of the NTP phosphates are shown. Modified
from Nudler (2009)
the un-folded conformation, the TL is far away from the active centre to be able to participate
at the catalysis. When the reaction occurs, after the nucleoside monophosphate (NMP) incor-
poration, pyrophosphate (PPi) is released and TL returns to the unfolded conformation.
The active center of RNAP is responsible for catalysis of nucleotide addition but is also able to
perform hydrolysis by catalysing pyrophosphorolysis and phosphodiester bond hydrolysis (Fig.
1.3) in the same active center with the general two Mg2+ ion mechanism. All of these reactions
are catalysed from different translocation states of the RNAP and both the TL and Mg2+ (I and
II) play a crucial role.
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Figure 1.3: RNAP reactions.
(A) Steps of nucleotide addition, RNA (red), DNA (black) Mg2+ (yellow), NTP (green).
(B) Pyrophosphorolysis (top) and phosphodiester bond hydrolysis (bottom). Modified from
(Buc and Strick, 2009)
1.1.2 Transcription cycle
The RNAP is able to bind the DNA and proceed through thousands of base pairs without losing
contact with the DNA and RNA to produce a new RNA chain. As mentioned previously, the
core-enzyme of the RNAP is not able to start the transcription reaction. The enzyme required
a sigma factor to recognise and bind the promoter region of the DNA template that specifies
where transcription starts (Wade et al., 2006). Bacterial transcription is a complex and tightly
regulated process in the cell composed of three stages:
(i) Initiation, during which the RNAP holo-enzyme (core plus sigma) binds to the DNA and
forms the promoter complex;
(ii) Elongation of the nascent RNA chain;
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(iii) Termination, during which the RNAP encounters a signal that causes it to stop transcription.
The three phases are represented in the Fig.1.4 along with a list of different drugs that are known
to inhibit each of the steps of the cycle (described in the next paragraph).
1.1.2.1 Transcription initiation
Initiation is the most regulated step of transcription. This phase begins with the recognition of
the promoter by the core enzyme equipped with the transcription initiation σ factor (Park et al.,
1982; von Hippel, 2007). Sigma factors play important roles at different stages of initiation
including a direct recognition of promoter to form an initial “closed” complex (RPc), followed
then by a stabilisation of the “open” complex (RPo) in which the melted DNA is around the tran-
scription start site. In E. coli, there are seven σ factors, each one of which is able to recognize a
specific subset of promoters for the expression of genes induced under different environmental
stimuli (Ghosh et al., 2010). Specifically, σ70 is the one responsible for the bulk of transcrip-
tion during growth (Paget, 2015). By moving along the DNA template the holo-enzyme is
capable to recognise and bind to the promoter (Sakata-Sogawa and Shimamoto, 2004). σ70-
RNAP holo-enzyme binds to promoters with conserved recognition motifs centred at positions
-35 (TTGACA) and -10 (TATAAT) upstream of the transcription start site (position +1) (Ghosh
et al., 2010; Paget and Helmann, 2003). Upon binding to a promoter, the holo-enzyme begins
to melt the DNA duplex around the transcriptional start site. This process leads to the formation
of transcription bubble, which is a stable open promoter complex set to initiate RNA synthe-
sis. RNAP then enters into abortive initiation cycle synthesising short RNA oligonucleotides
(around 8-9 nt). The transition to productive elongation is made when one of these short RNA
oligonucleotides is extended to 8-11 nucleotides in length (Revyakin et al., 2006). This process
is known as promoter escape and it ends with the release of the σ subunit (Reppas et al., 2006).
1.1.2.2 Transcription elongation
Important conformational changes in RNAP and in particular σ-core interface switch the initi-
ation complex into the highly stable and processive elongation complex (EC). The size of the
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Holo-enzyme
assembly
Closed 
complex
Open
complex
Abortive 
inhitiation
Elongation
Termination
Lpm
Myx
Cor
Rip
Sor,
SB2
Figure 1.4: Three stages of transcription are shown. i) Initiation. RNAP bound to σ factor
recognises a specific promoter in the DNA and binds to it forming the “closed promoter com-
plex”. Through a series of interactions between DNA, both σ and RNAP melt the DNA thus
forming “open promoter complex”. RNAP begins RNA synthesis in an abortive manner until
an RNA chain is around 8-9 nucleotide long. At this point, RNAP is capable to escape from
the promoter. After σ has been released, RNAP enters (ii) transcription elongation where the
highly processive synthesis of RNA is achieved. (iii) Termination. RNAP finishes the transcrip-
tion interacting with an inverted repeat palindromic sequence followed by a poly A sequence on
the DNA, this sequence in known as terminator which causes destabilisation on the DNA:RNA
hybrid which leads to RNA release. The steps that are inhibited by the antibiotics are indi-
cated by the arcs. Lpm- lipiarmycin, Myx- myxopyronin, Cor- corallopyronin, Rip- ripostatin,
Rif- rifampicin, Sor- sorangicin, Stl- streptolydigin, and MccJ25- microcin j25, GE- GE23077.
Modified from (Buc and Strick, 2009)
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transcription bubble (14 ± 1 nt) and RNA-DNA hybrid (9 ± 1 bp) is thought to be kept constant
by the EC until the termination signal is reached (Kireeva et al., 2000).
Elongation involves the recognition of the correct nucleoside triphosphate (NTP), its incorpo-
ration to the 3’ OH of the nascent RNA chain through formation of the phosphodiester bond
derived by the release of pyrophosphate (PPi) and finally the translocation of RNAP by one
nucleotide. In E. coli the transcription elongation complex is capable of continuous synthe-
sis of RNA chains thousands of nucleotides long at an estimated rate of 70 nt/s (Gotta et al.,
1991). Similar to transcription initiation, the elongation phase of the transcription cycle is sub-
ject to regulation, which is achieved through pausing and termination mechanisms (Uptain et al.,
1997). The main difference between these two is that pausing does not cause disassociation of
the EC whereas termination does (McDowell et al., 1994).
1.1.2.3 Transcription termination
RNA synthesis proceeds until the RNAP encounters a termination signal. There are two mech-
anisms of transcript termination in bacteria; Rho-independent, and Rho-dependent termination.
In the first one, the elongation complex stops upon reaching a termination sequence. The ter-
minator sequences feature a GC-rich palindromic element immediately followed by a series of
T in succession, therefore the nascent RNA adopts a hairpin structure,which inactivates the EC
by displacing the RNA from the RNA:DNA hybrid and the RNA exit channel (Epshtein et al.,
2007; Gusarov and Nudler, 1999; Komissarova et al., 2002). The EC then rapidly dissociates
and RNAP is able to start the transcription cycle again.
In the second mechanism, ‘Rho-dependent termination’, RNAP stops with the assistance of the
Rho, a terminator factor that binds to an 80-100 nucleotide C-rich segment in the nascent RNA
(Epshtein et al., 2010; Richardson, 2002). Rho with its helicase activity was the first termi-
nation factor to be identified but the actual mechanism by which it reaches the EC is not well
known. This kind of termination is a two-step process that requires rapid EC inactivation and
a moderately slow dissociation (Epshtein et al., 2010). Once transcription has been terminated,
RNAP is again free to restart a new round of transcription.
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1.2 Transcription as an antimicrobial drug target
1.2.1 Background
The use of antibiotics dates back to in ancient Egypt in Greece and in China where molds,
soil, and plants were used to treat bacterial infections (Forrest, 1982). However, the modern
era of utilization of antibiotics from natural product (secondary metabolites), began in 1928
when a Scottish biologist, Alexander Fleming, noticed growth inhibition in a plate cultured
with Staphylococcus which was caused by the growth of a contaminating fungus, Penicillum
notatum. Fleming was able to isolate the active compound which he named penicillin.
Penicillin has broad spectrum activity against Gram positive bacteria, and its use was extremely
important during the Second World War. Fleming was awarded the Nobel Prize in Medicine
in 1945 together with Ernst Boris Chain and Howard Florey, who devised a method for mass
production. During his Nobel lecture, Fleming warned against the possibility of development of
antibiotic resistance, saying that “it is not difficult to make microbes resistant to penicillin in the
laboratory by exposing them to concentrations not sufficient to kill them, and the same thing has
occasionally happened in the body” (Maurois, 1959). Indeed, the increasing amount of resistant
organisms is now producing a human health crisis, as we are assisting to the emergence of new
pathogens that are resistant to all available antibiotics. The resistance to antibiotics is attributed
to their overuse of misuse. On the other end, the discovery of new compounds significantly
slow down over the past years (Fig. 1.5).
Antibiotics that target bacterial cells generally act by inhibiting one of four main vital pro-
cesses for cell: (i) cell wall biosynthesis (e.g. β-lactams), (ii) proteins synthesis (e.g. Tetra-
cyclines) (iii) DNA replication and RNA synthesis (e.g. Quinolones and Rifampicin) (iv) folic
acid metabolism (e.g. Sulphonamides) (Lewis, 2013).
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Figure 1.5: The timeline of antibiotic discovery and introduction. Blue: year of introduction.
Red: Year of discovery. Modified from (Lewis, 2016)
1.2.2 Resistance
The utilization of antibiotics has closely followed by the development of resistance mechanism,
a gained characteristic that increases the minimum inhibitory concentration (MIC) of a bacterial
strain, where MIC is defined as the minimal concentration of drug that prevents visible bacte-
rial growth (Minimum Inhibitory Concentration). The antibiotic resistance can be classified
into two type, Intrinsic and Acquired resistance. The first one, is the innate ability to resist to an
antimicrobial agent through its inherent characteristics. The mechanism of Intrinsic resistance
are of four type: (i) lack of affinity of the drug for the target (ii) inaccessibility of the drug into
the cell wall (iii) existence of enzymes that inactivate the drug and (iv) extrusion of the drug
by exporters (Cox and Wright, 2013). The second one, the acquired mechanism to gain resis-
tance, occurs when a specific pathogen obtains the ability to resist to an antibiotic. This kind
of resistance can be developed by two different ways: spontaneous de novo mutations, or by
incorporation of external genetic material via horizontal gene transfer (HGT). The mechanisms
responsible for acquired resistance are primarily of three types: (i) alteration of the drug target
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that causes reduced target susceptibility (ii) modification the drug, with subsequent decrease
drug-target affinity; (iii) reduction of drug concentration that can reach the target, either via
increased drug efflux or decreased drug influx
1.2.3 Antibiotics blocking nascent RNA extension
RNAP is an optimal target for the development of specific antibiotics for different reasons.
First, it is a central enzyme for cell survival, second the structure of RNAPs is highly conserved
between bacteria, but is less conserved between eukaryotes and bacteria, and third the regu-
lation of transcription is different between prokaryotes and eukaryotes, and therefore with the
possibility to find drugs active only against prokaryotic RNAP. Several molecules, both natural
and synthetic are known to inhibit different stages of the transcription cycle (Table 1.1, adapted
from Gualerzi et al. (2013), (Fig. 1.6). Among these molecules, Rifampicin (Rif) and its anal-
ogous have reached clinical use and are first-line antibiotics for the treatment of tuberculosis.
In 2011, a second RNAP-targeting antibiotic, Lipiarmycin (Lpm) was approved for clinical
use under the name Dificid (Optimer Pharmaceuticals, USA) for the treatment of Clostridium
difficile infections (Sears et al., 2013).
According to the mechanism of inhibition and target site (if known), the antibiotics that inhibit
RNAP can be divided into four groups:
(i) compounds that block nascent RNA extension,
(ii) compounds with target RNAP active centre,
(iii) compounds that block promoter complex formation,
(iv) compounds that hinder the σ–core interactions.
The Fig. 1.6 shows the main structure of transcription inhibitors.
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Tagetitoxin
Figure 1.6: Chemical structures of transcription inhibitors.
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1.2.3.1 Compounds that block nascent RNA extension
Ansamycins (Rifampicin)
Ansamycins are a large family of compounds produced by Actinomycetales (Mariani and Maf-
fioli, 2009). Rifamycins, isolated by Piero Sensi and co-workers in 1959 (Sensi et al., 1958)
from Amycolatopsis mediterranei are the more potent antibiotics of this family. Rifamycins are
mainly effective against mycobacteria and are used against tuberculosis, leprosy, and other in-
fections. The rifamycin group includes the "classic" rifamycin antibiotics and their derivatives,
such as rifampicin (Rif), rifapentine, rifabutin, and rifalazil (Fig.1.6) (Acocella, 1978). This
class is characterized by a cyclic structure, with an aromatic moiety bridged by an aliphatic
chain (ansa ring). Different compounds present variations is in the structure of the “tail”, that it
is attached to the ansa ring, at either C3 or C3/C4 position (Fig. 1.7a)
In 2001 the Darst group was able to obtain the crystal structure of Taq core RNAP with Rif
(Campbell et al., 2001). Rif binds DNA/RNA channel through the interaction with RNAP β-
subunit residues, approximately 12 Å away from active site. It has been demonstrated that Rif
binds to 12 amino acid residues in RNAP (Campbell et al., 2001) blocking RNA synthesis after
3-4 nucleotides during initiation but without affecting the elongation complex (EC). Additional
studies of Rifapentin and Rifabutin, analogues of Rif, showed a different mechanism of action,
an allosteric movement that moves around 20 Å and it decreases the affinity to Mg2+ (required
for catalytic activity) (Artsimovitch and Vassylyev, 2006). The structure of the tail seems de-
termine the target C3 rifamycins inhibits the formation of the second phophodiester bond and
C3/4 rifamycins inhibit even the first phophodiester bond.
Two different mechanism of action Fig.1.7 of Ansamycins class has been identified: the “β-
pathway” and “σ- pathway”. The first one, activated by interaction between ansa-ring and beta
residues, inhibits the formation of the second phosphodiester bond. This pathway is common
among all rifamycins and it is independent of the tail configuration. The σ-pathway is acti-
vated by the interaction between the tail and the σ-subunit, and it inhibits the formation of the
first phosphodiester bond formation. This second pathway followed only by the C3/C4 class
(Artsimovitch and Vassylyev, 2006).
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A B
C
Figure 1.7: A model of Rifampicin action.
(A) Structure of the ansa backbone of Rifamycins with structure of the tails C3 and C3/C4.
(B) The steric model for Rifampicin action. The core RNAP is represented in light-grey, the
catalytic the bridge in dark-grey, the σ factor in magenta, the template DNA in red and non-
template in dark blue, new RNA in yellow. Magenta circle is Mg2+ in the active site. (C)
pathway mechanism of Rif action, The β pathway (blue) and the σ pathway (magenta). Modified
from Vassylyev G.D Cell Cycle 5:4, 399-404
Bacterial resistance to RNAP inhibitors is consequence of either a change in the enzyme struc-
ture or a decrease in access to the target site for inactivation/decrease cell-membrane perme-
ability of the drug due to mutations. Rifampicin, interacts only with the β-subunit of RNAP
encoded by rpoB gene (?) and spontaneous resistance to Rifampicin is mainly associated with
single point mutations with consequent amino acid change.
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Sorangicin
Sorangicin (Sor) is a macrolide polyester antibiotic (Fig. 1.6) produced in two structural vari-
ants (A and B) by Myxobacterium Sorangium Cellulosum (Jansen et al., 1985). Sor is an an-
tibiotic with highest level activity against Gram-positive bacteria but it has reduced activity
against Gram-negative bacteria. The complete chemical synthesis of Sor has been described
and hundreds derivatives have been synthesized. Sor is specific for bacterial RNAP and not
for eukaryotic RNAPs and efficiently inhibits both E. coli RNAP and Taq (Irschik et al., 1987;
Schummer et al., 1993; Campbell et al., 2005).
The structure of the Taq RNAP core-enzyme in complex with Sor was resolved to 3.2 Å res-
olution in 2005, revealing an almost complete overlap between the Sor- and Rif-binding sites
(Campbell et al., 2005). The mechanism of inhibition is essentially the same as for Rif, i.e.
by blocking the synthesis of the second phosphodiester bond as a consequence of the steric
clashing with nascent RNA transcripts (Campbell et al., 2005).
There are three kinds of rpoB mutations in the Sor/Rif-binding pocket. The group I-mutations,
leading for both Rif- and Sor resistance (Rifr/Sors), involve the critical interactions for antibiotic
binding. The group II-mutations, conferring Rif-resistance and sensitivity to Sor (Rifr/Sors),
create distortions in the antibiotic-binding site that abolish Rif binding and have almost no ef-
fect on Sor binding. The group III-mutants, conferring resistance to Sor and sensitive to Rif
(Rifs/Sorr), involve β subunit residues 513 and 574 which form critical hydrogen bonds with
Rif and Sor. The conformational plasticity of Sor gives this antibiotic an advantage above Rif
and makes it a promising candidate for the treatment of Rif-resistant pathogens (Römmele et al.,
1990).
Tagetitoxin
Tagetitoxin (TGT) is a toxin isolated from the plant pathogenic bacterium Pseudomonas sy-
ringae pv. tagetis (Mitchell and Durbin, 1981). TGT causes chlorosis in leaves, which was
attributed to inhibition of RNA polymerase in chloroplasts (Mathews and Durbin, 1990). TGT
inhibit the eukaryotic RNA polymerase III (but not RNAPs I and II), and was found to inhibit
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also bacterial RNA polymerase (Mathews and Durbin, 1990). Structure of this compound have
been proposed (Mitchell and Durbin, 1981; Mitchell et al., 1989; Gronwald et al., 2005), and
the last proposed structure was published very recently (Aliev et al., 2016).
The study of tagetitoxin in complex with T. Thermophilus RNAP prove that it binds in the sec-
ondary channel closely but not overlapping the active centre (Vassylyev et al., 2007). Recently
Yuzenkova et al. (2013) demonstrated a possible mode of action, of which suggested that TGT
does not affect the chemistry of RNA synthesis or competes with the nucleoside triphosphate in
the active centre. Instead, TGT increases the stability of the pre-translocated state of the elon-
gation complex, consequently slowing down the addition of the following nucleotide. It was
also proposed that TGT is capable of interacting with the flexible domain of the active center
the Trigger Loop (TL), in fact by stabilising the folded conformation of the TL in the pre-
translocated state in elongation (Yuzenkova et al., 2013). One consequence of this stabilization
is, for example, the decreasing of the backtracking process (Nudler, 2012).
1.2.3.2 Antibiotics targeting RNAP active centre
Streptolydigin
Streptolydigin (Stl), or portamycin, is an antibiotic produced by Streptomyces lydicus (Fig. 1.6),
it has been isolated in 1955 by researchers at the UpJohn Company (Deboer et al., 1954) and it
is a component of the acyltetramic acids (3-acyl-2,4-pyrrolidinediones) group of natural prod-
ucts, which possess a broad spectrum of biological activities as antibacterial, anticancer and
antiviral compound (Crum et al., 1955; Deboer et al., 1954). Stl is active against Gram-positive
bacteria such as Staphylococcus, Streptococcus, Bacillus and Corynebacterium, whereas E. coli
and other Gram-negative bacteria are resistant to Stl due to its low membrane permeability. Stl
is a bacteriostatic inhibitor of initiation, elongation and pyrophosphorolysis in bacterial RNAP
(Temiakov et al., 2005a), and it is not active against eukaryotic RNAPs (Plevani et al., 1975).
Biochemical studies explained that Stl decreases the rate of NTP addition and inhibits mRNA
cleavage through the elongation factor GreA, but it does not influence substrate binding and
phosphodiester bond formation (Temiakov et al., 2005b). Stl entraps the bridge-helix of the
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RNAP and induces opening of the trigger-loop. Afterwards, it stabilizes the inactive intermedi-
ate state and blocks structural isomerization of RNAP into an active state, which needs confor-
mational changes of bridge-helix and the trigger-loop moieties (Tuske et al., 2005; Vassylyev
et al., 2007), and its binding region is situated approximately 20 Å away from the rifamycins
binding site (Heisler et al., 1993; Tuske et al., 2005). As a result of this biochemical mecha-
nism of RNAP inhibition and a distinct binding site, streptolydigin and rifamycins display only
minimal cross-resistance (Xu et al., 2005).
Microcin J25 and Capistruin
Microcin J25 is a cyclic 21-residue lasso peptide produced by E. coli strains carrying the pTUC
plasmid encoding the four-gene cluster mcjABCD (Salomon and Farías, 1992). MccJ25 has
dimension of 30Å x 15Å with a comma shape (Mukhopadhyay et al., 2004). This peptide has
been demonstrated to contain an incredible structural fold complementary to RNAP secondary
channel, in both size and shape. It completely encloses RNAP secondary channel like a “cork in
a bottle” and its inhibition occurs at the level of NTP uptake or NTP binding RNAP (Adelman
et al., 2004; Mariani and Maffioli, 2009; Mukhopadhyay et al., 2004). Transcription in vitro
assays showed that MccJ25 inhibits both formation of abortive products and formation of the
full-length product, without blocking the open promoter complex formation (Mukhopadhyay
et al., 2004). Obstruction of RNAP secondary channel represents a new mechanism of inhibition
of RNAP and an attractive target for antibacterial drug discovery, but the detailed mechanism
of MccJ25 action is not well understood.
MccJ25 inhibits the pyrophosphorolysis reaction performed by the RNAP catalytic site sepa-
rately of NTP uptake, suggesting that the mechanism may not be a simple competition with
incoming NTPs (Adelman et al., 2004). There are two types of MccJ25-resistance mutations.
The first type of mutation includes four genes that encode cell membrane proteins, especially a
principal receptor responsible for its import. The second type is located in β’ subunit TL (i.e.
E. coli T931I) (Delgado et al., 2001).
It has been discovered that the majority of MccJ25r mutations are located in the secondary
channel, and there are no mutations leading to cross-resistance with Stl and MccJ25. However,
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Stlr mutations in the β subunit ‘Stl pocket’ confers the resistance to MccJ25 suggesting similar
mechanisms of action. Furthermore, the effect of the mutations was demonstrated to be indirect
because MccJ25 is binding in the secondary channel (Yuzenkova et al., 2002).
Recently, a new peptide, Capistruin, was identified from Burkholderia thailandensis. Capistruin
inhibits Gram-negative bacteria, it is structurally similar to MccJ25 and was shown to inhibit
wild-type E. coli RNAP but not MccJ25-resistant RNAP, suggesting a similar binding sites and
mechanisms of action (Knappe et al., 2008; Kuznedelov et al., 2011).
CBR compounds
A novel class of inhibitors, CBR compounds, was isolated in 2003 with an high-throughput
screening (HTS) of a large library of chemical compounds followed by transcription assay with
E. coli RNAP core-enzyme and holo-enzyme. The CBR703, CBR9379 and CBR9393 specif-
ically inhibit RNAP (Cox and Wright, 2013) during and elongation by stabilizing elongation
complex isomerization and slowing translocation (Malinen et al., 2014). They displayed low
or no activity against Gram-positive or Gram-negative species supposed to be due to the spe-
cific efflux of the compound. Biochemical and genetic data suggested that CBR703 binds to
the surface of RNAP and stops catalytic reactions of the active site, NTPs addition and PPi-
driven hydrolysis. CBR703 does not involve the translocation of RNAP along the DNA and
because its binding site is located far from the RNAP catalytic site, the mechanism of inhibition
is non-competitive and allosteric (Artsimovitch et al., 2003).
1.2.3.3 Antibiotics blocking promoter complex formation
Myxopyronin
Myxopyronin (Myx) is an α-pyrone antibiotic, isolated from the Myxococcus fulvus in 1983
(Irschik et al., 1983) as a mixture of two forms (A and B). Myx is active against a broad spectrum
of Gram-negative and Gram-positive bacteria including Staphylococcus aureus, Enterococcus
faecium, Pseudomonas aeruginosa, Mycobacteriumtuberculosis and Escherichia coli but it is
not active against eukaryotic RNAPs (Irschik et al., 1983).
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Myx inhibits RNAP during transcription initiation and not during the elongation phase; specif-
ically, it inhibits the formation of the RNAP open promoter complex when bound to RNAP be-
fore DNA binding (Belogurov et al., 2009; Lira et al., 2007). The crystal structures of Thermus
thermophilus RNAP in complex with Myx show that it binds to the RNAP. It binds inside a pre-
dominantly hydrophobic binding pocket formed by adjacentby segments of β and β’ of RNAP
(Srivastava et al., 2011). Two hypotheses explaining the mechanism of action of Myx were
suggested. The first one, known as ‘hinge jamming’ hypothesis (Mukhopadhyay et al., 2004),
suggested that Myx prevents RNAP clamp opening, and consequently it prevents binding of
promoter DNA ( DNA regions -11 to +15) into the main channel. The second hypothesis pro-
poses that Myx prevents the β’ switch2 refolding and the loading of the template single-stranded
(ssDNA) into the RNAP active site cleft (Belogurov et al., 2009).
Myx is a promising antibiotic because it has good activity against a variety of pathogens and
it does not present cross resistance with Rifampicin. Only a few of cross resistance with other
drugs have been observed targeting switch-2 region, as corallopyronin, and ripostatin (Bel-
ogurov et al., 2009; Mukhopadhyay et al., 2008).
Lipiarmycin
Lipiarmycin (Lpm) also known as fidaxomicin, is a macrocyclic antibiotic isolated from Actino-
planes deccanensis (Coronelli et al., 1975). Lpm has antibacterial activity against Gram-positive
bacteria like Clostridium difficile, Enterococcus faecalis and Bacillus subtilis, and good activity
against Rifr of Mycobacterium tuberculosis (Kurabachew et al., 2008; Ma et al., 2013). Lpm
was recently FDA-approved in 2011 for treatment of Clostridium difficile infections under the
name of Dificid (Optimer Pharmaceuticals, USA) (Cornely et al., 2012).
Lpm blocks transcription initiation of RNAP with the half maximal inhibitory concentration
(IC50) approximately circa 3–10 µM and it is not active against eukaryotic RNAP II (Sonen-
shein and Alexander, 1979); it blocks isomerization from the closed promoter complex to open
promoter complex and it does not influence transcription if added after the formation of the
RPo (Tupin et al., 2010a). Lpm binds upstream edge of the main channel at the entry of the
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RNA-exit channel, it targets different main elements of the RNAP mobile clamp domain, such
as the β’ subunit Zn-finger etc. Furthermore, a specific dependence of Lpm with σ subunit has
been demonstarte, Lmp binds σ70 subunit (3.2 region) and RNAP β subunit (switch-2 element)
which conducts the clamping of the promoter DNA in the active site clef (Tupin et al., 2010a).
Ripostatin
Ripostatins (Rip) was isolated from Sorangium cellulosum strain as a mixture (A and B), each
of them is a macrocyclic lactone carbonic acid (Glaus and Altmann, 2012). Rip is less effective
than Myx and active mostly on Gram-positive bacteria such as Clostridium difficile, Staphy-
lococcus aureus, Enterococcus faecium, but is active against only one Gram-negative species
(Moraxella catarrhlis). The very limited activity against Gram-negative bacteria is due to the
low permeability of their outer membrane, in fact Rip displayed good activity on E. coli strain
carrying the mutations of the genes involved in the membrane lipolysaccharide (LPS) assembly
(Srivastava et al., 2011).
In vitro Rip inhibits transcription by E. coli RNAP but it does not affect eukaryotic RNAP II
(Mukhopadhyay et al., 2008; Irschik et al., 1995). Mutagenesis data showed overlap between
the Myx and Rip binding sites, and indeed it has been demonstrated that Rip inhibits tran-
scription essentially in the same way as Myx, by blocking the formation of the RPo complex
(Mukhopadhyay et al., 2008).
1.2.3.4 Inhibitors hindering σ–core interactions
SB2 and Analogues
A new collection of small molecular compounds was isolated from the ChemBridgeT M chem-
ical library by high-throughput screening (HTS) based on the in vitro assay for σ–core inter-
actions (André et al., 2005). The main compound is known as SB2 and, as do the structurally
similar class of compounds (e.g. SB7; SB8; SB11 and SB15) inhibit holo-enzyme assembly
(André et al., 2004).
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These inhibitors were active against Gram-positive and Gram-negative bacteria, with the main
activity against Gram-positive Bacillus anthracis, Streptococcus pneumonia, Bacillus cereus,
Staphylococcus epidermidis and Staphylococcus aureus. SB2 is not active against Mycobac-
terium tuberculosis, Pseudomonas aeroginosa, or wild type E. coli strains, but is active against
E. coli D22 (a strain characterized by more permeability) (Villain-Guillot et al., 2007; Glaser
et al., 2007)
Biochemical studies have shown that the target site of SB2 is located on the RNAP core and
the mechanism of inhibition is achieved by obstructing contacts between the σ subunit and
catalytic core. No resistance mutations have been identified yet, preventing mapping of the
inhibitor binding site (André et al., 2005).
1.2.3.5 Inhibitors with unknown mechanisms
Ureidothiophene and others
Ureidothiophene (2-ureidothiophene-3-carboxylate) is a low molecular-weight inhibitor iso-
lated from a commercial library of 250,000 available compounds with High-throughput screen-
ing HTS using an in vitro transcription assay with the Staphylococcus aureus RNAP holo-
enzyme. It is active against Rifr RNAP of Staphylococcus suggesting an alternative mechanism
of action or binding site on the holo-enzyme RNAP compared to Rif binding site on the β
subunit (Arhin et al., 2006).
Thiolutin and Holomycin are natural products that inhibit bacterial transcription, isolated from
Streptomyces luteosporeus and Streptomyces clavuligerus, respectively (Seneca et al., 1952;
Oliva et al., 2001). Their mechanism of action is still unknown.
Etnangien is another natural product from Sorangium cellulosum that has activity against only
Gram-positive bacteria (Irschik et al., 2007). It shows no cross-resistance to Rif, and it shows
inhibition against RNAP in vitro and in vivo but the mechanism is not clear Li et al. (2009).
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Chapter 2
Aims
The screening of antibiotics that target transcription from Actinomycetes collection could result
in the isolation of novel, uncharacterised compounds. For this reason, the ultimate aim of this
project is to characterise and uncover the mechanisms of action of such compounds through
the systematic analysis of the properties of these inhibitors in vitro. The findings obtained here
could be used to find potential antimicrobials of clinical interest and also to further develop our
fundamental understanding of the function of RNAPs.
Many important insights about the structure and function of macromolecular complexes have
been obtained by studying the action of inhibitors. Previously, in Prof. Zenkin’s lab several
RNAP inhibitors have been studied leading to the discovery of previously unrecognized fea-
tures of RNAP catalysis (Zenkin et al., 2005; Yuzenkova et al., 2013).
To summarize, the main two goals of this project were:
1. Find one or more novel transcription inhibitors of RNAP
2. Through systematic analysis of such compounds uncover their mechanism of action, and use
them as well to better understand the functioning of RNAPs.
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Chapter 3
Material and Methods
3.1 Purification of RNAPs
3.1.1 Purification of E. coli RNAP
All wt RNAP subunits were expressed in T7 Express Competent E. coli cells (New England
Biolabs) transformed with the pGEMABC plasmid, encoding for rpoA, rpoB and rpoC, and
pRSFD2rpoZ encoding for rpoZ gene. The procedure was performed as previously described
in (Murakami, 2013). The cells were transformed and plated onto LB/Amp (50 µg/ml)/Kan (50
µg/ml). Briefly, 8 litres (L) of LB media (100 ug/ml Amp, 50 ug/ml Kan) were inoculated with
1/100 volumes from a 50 mL overnight culture. The cells were grown at 25 °C with shaking
at 300 rpm, until an OD595 of 0.8 was reached, then IPTG (Melford) was added to a final
concentration of 0.5 mM and the cells were grown for an additional 3h at 25 °C . The cells were
centrifuged at 7000 rpm using the JLA-8100 rotor (Beckman) for 15 min. All purification stages
were performed at 4°C . The cell pellet was resuspended in lysis buffer (100ml per 10g frozen
cells) (50 mM tris-HCl pH7.9, 1 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF). After resuspension,
the cells were sonicated at 60% amplitude, 3 sec on, 3 sec off for 10 min, in an ice-water bath.
The cell debris was separated from the crude extract by centrifugation at 18000 rpm using a
JA-25.50 rotor (Beckman) for 20 min. The supernatant collected and transferred to a 250 mL
Erlenmeyer flask and polymin-P (polyethyleneimine, Sigma) was added to a final concentration
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of 0.8% (stock solution 6% pH 7.9). The sample was stirred at 4 °C for 10 min followed by
centrifugation at 8000 rpm using the JA-10 rotor for 9 minutes. The pellet was resuspended in
approximately 80 mL of ice-cold TGED (10 mM tris-HCl, pH 7.9, 5% glycerol, 0.1 mM EDTA,
0.1 mM DTT) + 0.5 M NaCl and homogenized using a glass homogenize. After resuspension
the sample was centrifuged at 8000 rpm with the JA-10 rotor for another 9 min. The latter step
was repeated twice. The pellet was resuspended in approximately 50 mL of TGED + 1M NaCl,
homogenized and spun down at 8000 rpm for 9 min, twice. Slowly 35g of ammonium sulphate
(NH4)2SO4 per 100 ml (final 60% saturation) of supernatant was added and stirred at 4°C room
overnight at 4°C .
The precipitated sample was spun down at 18000 rpm in a JA-25.50 rotor for 20 min. The
obtained pellet was dissolved in 50 mL of TGED without salt and a second centrifugation
step was performed. The crude protein extract was filtered through a 0.45 µm Millipore filter.
The solution was applied to a HiTrap Heparin HP (GE Healthcare) pre-equilibrated with TGED
buffer A (TGED+0.1M NaCl) at a flow rate of 1 mL/min. The protein was eluted with a stepwise
gradient of TGED buffer B (TGED+1 M NaCl) from 0% to 100 % and the peak fractions
collected and analysed by SDS-PAGE. RNAP was mainly present in the peak fraction were
collected at 60% buffer B. The fraction containing RNAP was loaded onto a Mono Q anion
exchange column (Mono Q 5/50, GE Healthcare) pre-equilibrated with buffer A the same as
for the heparin column. The RNAP sample was loaded at a flow rate of 0.5 mL/min and the
elution was performed in a stepwise increase of buffer B (as for the heparin column). The
fractions containing the RNAP enzyme were pooled and concentrated using Centricon 20 device
(100.000 MW cut-off) (Millipore) to 2 mL and dialysed against storage buffer (20 mM Tris-HCl
pH8, 0.3 mM KCl, 1mM EDTA, 1mM β-mercaptoethanol, 50% glycerol).
3.1.2 Purification of E. coli RNAPr
The procedure for purification of Rifampicin-resistant RNA polymerases (Rifr) was slightly
different from the wt RNAP. The rpoB mutations were introduced into the pETL plasmid by
mutagenesis using QuikChange II site-directed kit (Stratagene) (Table 3.1). pETL plasmids,
carrying the mutation in rpoB, together with pRSFD2-rpoZ plasmid encoding for ω subunit
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were transformed into a plate onto LB/Amp (50µg/ml)/Kan (50 µg/ml) plate. 3 L of LB media
(100 µg/ml Amp, 50 µg/ml Kan) were inoculated with 1/100 volumes from a 50 mL overnight
culture. The cells were grown at 37 °C with shaking at 300 rpm, until OD595 =0.7. IPTG
(Melford) was added to a final concentration of 0.5 mM and the cells were grown for an addi-
tional 3 hours. The cells were harvested and sonicated as previously described. Subsequently,
the lysate was applied to a HiTrap Heparin HP column (GE Healthcare) and the obtained peak,
equivalent to the RNAPr was applied to a 5mL His-trap Ni2+-NTA column (GE Healthcare
). Prior to loading, the Ni2+-NTA column was stripped (with 100 mM EDTA and 1N NaCl),
recharged (with 0.1M NiCl2), and finally equilibrated with grinding buffer (20mM Tris-HCl,
0.6 mM Nacl, 5% glycerol). The column was then eluted three times with grinding buffer.
The first time with a concentration of 25 mM Imidazole, second time with 100 mM and finally
200 mM of imidazole. The three fractions, collected from the three elutions, were analysed
on an SDS-PAGE gel (Bio-Rad), which showed that the RNAPr was present in the 100 mM
Iimidazole.
The fractions with RNAPr were pooled and concentrated using a Centricon 20 device (100000-
MW cut-off) (Millipore) to 0.5 mL and dialised into in storage buffer as previously described.
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Table 3.1: List of primers used to create RNAPr
plasmid pGEMABC
D516V (GAC =>GTC)
rpoB_D516V_d: GCT GTC TCA GTT TAT G GTC CA GAA CAA CCC GCT G
rpoB_D516V_r: CAG CGG GTT GTT CTG GAC CAT AAA CTG AGA CAG C
S531L (TCC =>CTG)
rpoB_S531_d: AA ACGTCGTATC TTGGCACTCG GCCC
rpoB_S531_r: GGGCCGAGTGCCAAGATACGACGTTT
H526P (CAC =>CCG)
rpoB_H526Y_d: CTG AGA TTA CG CCG AAAC GTC GTAT
rpoB_H526Y_r: ATA CGA CGT TTC GGC GTA ATC TCA G
H526Y (CAC =>TAC)
rpoB_H526Y_d: CTG AGA TTA CGT ACA AAC GTC GTA T
rpoB_H526Y_r: ATA CGA CGT TTG TAC GTA ATC TCA G
I572F (ATC =>TTC)
rpoB_I572_d: CAT CGG TCT GTT CAA CTC TCT GTC CG
rpoB_I572_r: CGG ACA GAG AGT TGA ACA GAC CGA TG
Q513L (CAG =>CTG)
rpoB_Q513L_d: CCA GCC AGC TGT CTC TGT TTA TGG ACC
rpoB_Q513L_r: GGT CCA TAA ACA GAG ACA GCT GGC TGG
D516Y (GAC =>TAC)
rpoB_D516Y_d: GCT GTC TCA GTT TAT GTA TCA GAA CAA CCC GCT G
rpoB_D516Y_r: CAG CGG GTT GTT CTG ATA CAT AAA CTG AGA CAG C
H526R (CAC =>CGC)
rpoB_H526R_d: CTG AGA TTA CGC GCA AAC GTC GTC G
rpoB_H526R_r: CGA CGA CGT TTG CGC GTA ATC TCA G
3.1.3 Purification of Bacillus subtilis RNAP
The purification of His-tagged RNAP (provided by Yulia Yuzenkova) was performed exactly
as described in (Anthony et al., 2000). 3 Litres of LB + 0.5%glucose (without antibiotics)
were inoculated with 1/1000 volume of overnight culture and grown at 30°C with rapid agita-
tion (300 rpm) until the culture was harvested by centrifugation at an OD600 of 1.2. A small
sample was checked under the microscope to confirm the cells as Bacillus subtilis cells. The
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harvested cells were re-suspended in Lysis buffer P (300 mM NaCl, 50 mM Na2HPO3, 3 mM
β-mercaptoethanol, 5% glycerol, and complete EDTA-free mini protease inhibitor table, Roche)
and lysed by sonication. After centrifugation, B. subtilis RNAP was purified by His-trap Ni2+-
NTA column (GE Healthcare) as described before (section 3.1.3)
The elution fractions with B.subtilis RNAP were pooled and concentrated using a Centricon 20
device (100000 MW cut-off) (Millipore) to 0.5 mL and dialysed into storage buffer (50 mM
Tris–HCl pH 8.0, 50% glycerol, and 3 mM β-mercaptoethanol).
3.1.4 Purification of σ70
The wild-type σ70 subunit was purified from pET21 vector (provided by Aleksandra Bochkareva)
and transformed into BL21 DE3 cells (Agilent). The procedure was carried out as described in
(Borukhov and Goldfarb, 1993). Briefly, 6 L of LB were grown at 37 °C in an orbital shaker to
an OD600=0.6 was reached. The protein expression was induced by addition of IPTG (Melford)
to a final concentration of 1 mM. After 3h incubation the cells were centrifuged at 7000 rpm
using the JLA-8100 rotor (Beckman) for 15 min. The pellet was resuspended in 100 mL lysis
buffer (40 mM Tris-HCl pH 7.9, 0.3 M KCl, 10 mM EDTA, 0.1 mM DTT) with 2 protease
inhibitor cocktail tablets (Roche). The suspension was then homogenized using glass homoge-
nizer, and disrupted by sonication as described for RNAP. The lysate was centrifuged at 18000
rpm using a JA-25.50 rotor (Beckman) for 20 min. The pellet was resuspended in 50 mL of lysis
buffer with 0.5% Triton X100 and 1 mM DTT. A second round of sonication was performed
followed by centrifugation at 18000 rpm for 20 min. The obtained pellet was dissolve and incu-
bated in 10 mL denaturing buffer (50 mM Tris-HCl pH 7.9, 6 M guanidine-HCl, 10 mM DTT,
10% glycerol, 10 mM MgCl2, 1 mM EDTA, 10 µM ZnCl2) for 30 min at room temperature,
followed by centrifugation at 18000 rpm for 20 min. The final supernatant was diluted 2 times
with denaturing buffer and dialyzed overnight against 2L of reconstitution buffer (50 mM Tris-
HCL pH 7.9, 0.2 KCl, 20% glycerol, 10 mM MgCl2, 10 µM ZnCl2, 1 mM EDTA, 1 mM DTT).
The obtained dialyzate was cleared by centrifugation at 18000 rpm for 20 min in a JA-25.50
rotor and diluted 4 times with bufferE 4(0 mM Tris-HCl pH 8.3, 1 mM EDTA, 5% glycerol,
0.1 mM DTT) and loaded onto a 1.6 x 15 cm DEAE toyo pearl TSK 650 M column (Millipore)
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already pre-equilibrated with buffer E. To elute the protein, a linear gradient of buffer F (40 mM
Tris-HCl pH 8.3, 1 mM EDTA, 5% glycerol, 0.1 mM DTT, 0.6 M NaCl) was carried out, with
sigma protein eluting from the column between 30 – 50% of F buffer. The fractions containing
the σ70 enzyme were pooled and and dialysed against storage buffer (40 mM Tris-HCl pH 7.9,
0.2 M KCl, 50% glycerol, 1 mM EDTA, 1 mM DTT).
3.2 PCR
3.2.1 Preparation of T7A1 promoter fragment
Reverse Primer 5’ (Bio-CGACGTTGTAAAACGACGGCCAGTG)
Forward Primer 5’ (GGTCGACTCTAGAGGATCGCT)
Each 50 µl PCR reaction was prepared as follows: 0.7 µl plasmid ptz19 (100 ng/µL), 1 unit
of Phusion DNA polymerase (New England Biolabs), 0.4 mM final of each primers, 200 µM
dNTPS mixed in High Fidelity Buffer (#B05185New England Biolabs). Each reaction was
carried out (repeating for 35 cycles) as follows:
Table 3.2: T7A1 PCR condition
Temperature (°C ) Time (s)
98 30
98 9
72 18
}
35 cycles72 30
10 pause
The PCR products were purified from 1.5% agarose gels using the Gel Extraction Kit (Qiagen)
according to the manufacturer’s instructions.
3.2.2 Preparation of DNA template used for T7 RNAP transcription
Reverse Primer 5’ (AGGGCGCTTTAATTATGCTG)
Forward Primer 5’ (GCTCTCGATTTTCACTACTAC)
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Each 50 µl PCR reaction was prepared as follows: 0.5 µl DNA template, 1 unit of Phusion DNA
polymerase (New England Biolabs), 0.4 mM final of each primers, 200 µM dNTPS mixed in
High Fidelity Buffer (New England Biolabs). Each reaction was carried out (repeating for 33
cycles) as follows:
Table 3.3: PCR condition
Temperature (°C ) Time (s)
95 30
95 9
46 18
72 30
}
33 cycles72 30
4 pause
3.3 5’ 32P labelling of oligonucleotides
The unmodified T7A1 DNA (300 pmol) was incubated with 3 µL γ[32 P]ATP in the presence of
15 units of T4 Polynucleotide kinase (PNK) in reaction buffer A (Thermo scientific) with a final
volume of 30 µl. The reaction was incubated at 37°C for 60 min before PNK was deactivated
by heating at 65 °C for 20 min. The DNA was purified by filtration using MicroSpin P–30
chromatography Columns (Bio–rad) following the manufacturer’s instructions.
3.4 In vitro transcription assays
3.4.1 Transcription Initiation
A 287bp DNA fragment containing the wild type T7A1 promoter was prepared by PCR using
one primer bearing a biotin tag on the 5’ terminus (on the template DNA strand, Fig. 3.1).
The biotin tag allowed immobilisation of the template DNA required for some of the in vitro
transcription assays.
E.coli RNAP (2 pmol) was incubated with 15 pmol of σ70 and 0.2 pmol of T7A1 DNA in Tran-
scription Buffer (TB) (20 mM Tris-HCl, pH 7.9; 10 mM MgCl2; 40 mM KCl). The reaction was
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supplemented with 25 µM of dinucleotide CpA (or CpApUpC), 20 µM of ATP, GTP, CTP and
5 µM of UTP. α[32P] UTP was added (unless stated otherwise) and the final reaction was a final
volume of 10 µL. When required, compounds were added before or after the DNA fragment.
Reactions were incubated at 37 °C for 10 min and then stopped by the addition of an equal
volume of formamide containing stop buffer (7 M Urea, 20 mM EDTA, 100 µg/mL Heparin,
0.25% Bromophenol Blue and 0.25% Xylene Cyanol).
When performing transcption with B.subtils RNAP, the experiment was performed as for de-
scribed for E. coli RNAP
Transcription initiation in the presence of T7 RNAP was performed as as previously. The DNA
template was different as it was used a short template, and every reaction was carried out in
presence of DTT (final concentration 1mM).
(NT-DNA) ggtcgactctagaggatcgctataacaggcctgctggtaatcgcaggcctt
tttatttggatccagatcccgaaaatttatcaaaaagagtattgacttaaagtctaacct
ataggatacttacagccAtcgagagggacacggcgaatagccatcccaatcgacaccggg
gtccgggatctggatctggatcgctaataacaggcctgctggtaatcgcaggccttttta
tttggatccccgggtaccgagctcgaattcactggccgtcgttttacaacgtcg
Forward primer binding side
+1
Reverse primer binding side
- 10
- 35
(NT-DNA) agggcgctttaattatgctgagtgatatccctctgttgacaattaat
ttaatttaatttttcctttatttttacaaacatcatcacttttagctctcg
Forward primer binding side
Reverse primer binding side
T7 promoter
a)
b)
Figure 3.1: DNA sequences used in transcription assays
a) T7A1 promoter fragment. The sequence of the non-template DNA used for transcription
from promoter, -35 and -10 elements of the promoter and oligonucleotide binding sites (for
PCR reaction) are shown. The primer used for initiation is highlight in green and the +1 is
shown with capital letter ’A’.
b) DNA sequence of the non-template used for transcription with T7 RNAP. The primer used
for initiation is highlight and the T7 promoter is shown in red.
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3.4.2 Abortive assay
For the abortive transcription assays, the reactions were performed as for the transcription initi-
ation assay (section 3.2.1), but in the absence of specific NTPs. The reactions were carried out
in a final volume of 10 µl in the presence of TB with 25 µM of dinucleotide CpA (or CpApUpC)
5 µM of UTP and α[32P] UTP. Reactions were incubated at 37 °C for 5 min and then stopped
by stop buffer as above.
3.4.3 Elongation
wt E.coli RNAP was incubated with σ70 for 5 min at 37 °C in presence of T7A1 fragment,
then added a mixture of CpApUpc (50 pmol) with 25 µM of GTP, ATP, and CTP in presence of
α-[32 P]-GTP to obtaine EC20 (elongation complex featuring 20nt RNA). Streptavidin agarose
beads were added to the EC20 complex to allow DNA/RNAP complex immobilization to the
beads through the biotin tag present at 5’end of the DNA. The complexes were washed six times
with transcription buffer (without magnesium) to remove all unspecific complexes. Elongation
reactions were allowed to continue for 10 min at 37 °C, in presence or absence of the drug,
before being stopped by the addition of an equal volume of stop buffer as above.
All transcription reactions were analysed by denaturating PAGE on a 20% (unless otherwise
specified), and revealed by PhosphoImager (GE Healthcare), and quantified using the Image-
Quant software (GE Healthcare).
3.5 Electrophoretic mobility shift assay (EMSA)
The RNAP holo-enzyme was incubated with long T7A1 DNA, previously radio labelled as de-
scribed in section 3.4. After a 5 min incubation at 37°C , samples were supplemented with 1 µL
of compound and then stopped by adding stop buffer (50% glycerol, 0.2% bromophenol blue,
25 µg/mL heparin) sample were immediately loaded on a 4% non–denaturing polyacrylamide
gel (Native PAGE) made with TBE buffer. The gel was run for 30 min at 100V, and radioactive
bands were visualized by PhosphoImager and quantified using ImageQuant software.
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3.6 Potassium Permanganate DNA Footprinting
DNA was 5’32P radiolabelled by PNK enzyme(section 3.4). For each reaction 10 pmol of
RNAP was mixed with 2 pmol of labelled DNA in TB and incubated for 10 minutes at 37 °C .
The compounds, or the appropriate controls, were added at this stage and then the reaction
were kept for required length of time. KMnO4 was added at final concentration of 20 mM,
then the reaction proceed for 30 or 60 seconds. Before reactions were stopped by adding 400
mM β –mercaptoethanol. The DNA was extracted using phenol:chloroform:isoamyl alcohol
(25:24:1), followed by ethanol precipitation. The precipitated DNA was dissolved before in
90 µl of H20 10 µl of piperidine was added and incubated at 90 °C for 20 minutes. After the
reactions had cooled down, piperidine was removed with chloroform and DNA was ethanol
precipitated. The final DNA pellet was re-suspended in 20 µl formamide containing loading
buffer. The products were resolved on a 6% denaturating polyacrylamide sequencing gel and
analysed.
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Chapter 4
Preface
Over the last decade, the screening of microbial natural products (NP) as sources of novel
compound has been focused on those produced by Actinomycetes bacteria. It is well known
that synthetic and combinatorial libraries with high-throughput screening have not kept their
promise to generate new drugs. Presently, one of the reliable sources of natural products are
Actinomycetes bacteria, one of the largest and most diverse groups of bacteria found in almost
every environmental niche on the planet. The filamentous Actinomycetales bacteria produce
more than 45% of all antibiotics (Berdy, 2005), therefore, large biotech companies have begun
to screen vast collections of Actinomycete strains.
For this project, we had the opportunity to work with DemurisTM a biotech company, that
was established in 2008 by Prof. Jeff Errington in collaboration with Newcastle University.
DemurisTM has a collection of over 10,000 Actinomycete strains derived from both terrestrial
and marine environments. All of these strains were screened by a whole cell-based preliminary
assay using E.coli, S.aureus and B.subtilis. The strains with the ability to produce secondary
metabolites with an inhibitory effect against live bacteria were short-listed and given to our lab
to be tested against bacterial RNAP. Furthermore, a panel of reporter strains were used prior to
biochemical techniques to reveal preliminary information regarding the mode of action of these
inhibitory compounds:
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(i) a reporter strain which is an indicator of ansamycin-like molecule;
(ii) a reporter strain containing both bacterial and Phage T7 polymerase where the inhibition of
both RNAPs can be analysed individually using different reporter genes.
After screening, samples were processed (i.e. Organic extraction and Solid Phase extraction) be-
fore they were analysed in-vitro. The compounds of interest were purified using different chro-
matography techniques including using High-Performance Liquid Chromatography (HPLC),
organic extraction, Solid Phase Extraction (SPE), and Thin Layer Chromatography (TLC). Mass
spectrometry and NMR were used to obtain the mass and structure of the molecule after the in-
vitro activity of pure compound(s) were confirmed.
After this preliminary screening, in our lab, more than 100 extracts (as shown in the next Table)
were tested. From these extracts different main compounds were used for further investigation
in our in vitro assay. This confirmed that Actinomicetes are a main source of secondary active
metabolites which have the potential for the development of new antibiotics.
This project started with the analysis of the secondary metabolites given to us from the DemurisTM
Lab. These compounds were analysed in vitro to understand the mode of action of each of them.
First, we verified the solubility of the compounds given to us in our own solvent. The standard
protocol used was to check by eye to see if any precipitation was visible in each sample. Any
presence of precipitation was taken as an indicator that the compound was not soluble in this
solvent. If this was the case, the compound was dried and re-suspended in a different solvents
(as DMSO, EtOH or H20). Every stable sample was tested in vitro to verify whether or not it
was active against the RNAPs. If the compound displayed any inhibitory activity against RNAP,
a subsequent titration was done to identify the IC50 which is defined as the concentration of a
compound required for inhibition of 50% of the enzyme’s activity. Determining the IC50 enable
us to use the correct concentration of the compound for subsequent experiments.
After the identification, of active compounds the next step was to identify the specificity of
the inhibition against RNAPs from different bacterial species. Initially, three diverse species
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were chosen (E.coli, T7RNAP and B.subtilis RNAP) in order to understand the specificity of
the secondary metabolites against their RNAPs. The selectivity of a compound is the ability of
a drug to inhibit only the selected target. This is one of the most important characteristics for a
compound to be suitable for use as an antibiotic.
The compounds studied during this project were the ones specific for only one RNAP species,
that of E.coli. When a potential drug was found to be active against only one RNAP species,
further analysis was undertaken to understand which part of the transcription cycle was affected
(initiation, elongation or termination). To understand how transcription was affected was one of
the main goals during this project( as weel explained in chapter 5, 6 and 7) and each experiment
preformed is well described in the following results chapters. The following Table shows all
the drugs tested during the project, and a specificity description of initial assays for each one.
Outlined in the next chapters are three main compounds used for further investigation in our in
vitro assays.
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Chapter 5
DEM31376
5.1 Introduction
DEM31376 is an antibiotic with antibacterial activity against both Gram-negative and Gram-
positive bacteria. The Actinomycetes strain that produces this compound is a marine isolate
(unknown source) and, on the basis of the 16S rRNA gene sequence, it shares a similarity of
99.14% with Actinomadura mexicana. The isolation and purification of the compound was
carried out by our collaborators in DemurisTM lab, mainly by Hamed Mosaei Sejzi.
To identify the medium in which the Actinomycetes strain produced the highest amount of the
compound, the strain was grown for nine days in two different media, ISPII media (4 g/L yeast
extract, 10 g/L malt extract and 4 g/L glucose) and ISPII + soil. More compound was produced
in ISPII media, therefore this was used for all subsequent purifications (Figure 6.1-a [STEP 1]).
After growing the cultures, the cells were pelleted by high speed centrifugation and the cell-
free supernatant was used for isolation of the secondary metabolites. These metabolites were
obtained by first by non-ionic adsorption with Amberlile resins beads (ion exchange resins and
polymeric adsorbent) followed by reverse phase biotage HPLC (C18) (Figure 6.1-a [STEP2]).
Twenty secondary metabolites were purified by our collaborators in DemurisTM lab and tested
by using a zone of inhibition test for antimicrobial activity. This showed that three different
isolates were of particular interest. DEM31376/A, DEM31376/B and DEM31376/C (Figure
6.1-b [STEP3]).
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In parallel, the twenty secondary metabolites were also tested in an in vitro transcription assay
to determine the effect, if any, on wt E.coli DNA-dependent RNA polymerase (RNAP). In
this assay, transcription was initiated on a strong promoter (T7A1), and the ability of RNAP to
synthesize the full length transcript was analysed. After testing all of these extracts in vitro, only
DEM31376/A was seen to inhibit RNAPs. DEM31376/B and DEM31376/C were discarded as
they did not exhibit RNA inhibition during the transcription analysis. However, DEM31376/B
may be still of interest because it was found to interfere with the growth of bacterial cells in
liquid culture but via a mechanism of action that does not target RNAP.
The DemurisTM lab determined that DEM31376/A has a mass of 609.277 Da, and after it was
shown to be a potentially interesting compound, a second series of purifications were performed.
The same purification protocol was followed (Figure 6.1a [Step 1 to Step 3]) followed by an-
alytical HPLC and size exclusion HPLC (Sephadex-LH-20, Figure 6.1a [STEP4]) to obtain a
compound as pure as possible. HPLC resulted in two individual peaks which were collected as
separate fractions. The two fractions were named DEM31376-A1 and -A2 and were sent for
high resolution mass spectrometry (HRMS) (Fig. 6.1c).
Although there were differences during retention time on reverse phase-HPLC, HRMS data
suggested that the compounds in the two fractions were identical. HRMS revealed an accurate
mass of 610.28 Da with a H+ adduct for DEM31376-A1 and 632.266 Da for DEM31376-
A2, considered as 609.227 Da plus a Na+. These data showed that the difference between the
compounds in the two fractions consisted of only these two protons added to the same core.
DEM31376-A2 was chosen for further study, because it was the only one that showed activity
in our in vitro assays.
5.2 Aims
Our preliminary results showed that DEM31376-A2 inhibits RNAP. We, therefore, investigate
the inhibitory effect of this compound on bacterial RNA polymerase.
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Figure 5.1: Overview of the key steps involved in the isolation of DEM31376.
(a) ISPII media was used to grow DEM31376 strain. After growing for nine days [STEP 1], the
culture was mixed with non-ionic resin (Amberlile XAD-16N) used for adsorption of organic
substances from aqueous systems [STEP 2]. Production of the compound was monitored by
reverse phase biotage HPLC in the DemurisTM lab and tested against RNAP using an in vitro
assay. Three main fractions were collected (A-B-C) [STEP 3 and (b)] and, after an EtOAc ex-
traction, the activity was detectable only in compound A. In a second round of purification, a
subsequent chromatography step was used to further purify compound-A. NMR analysis and
hight resolution mass spectroscopy (c) showed that the compound occurs in two different vari-
ants [STEP 4], a 609.227 Da core with either a H+ ion or Na+ ion.
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5.3 Results
5.3.1 DEM31376-A2 is a Highly Selective Inhibitor of Bacterial RNAP
but not of T7-RNAP
In order to obtain basic information about the mode of action of the DEM31376-A2 frac-
tion (hereinafter referred to as DEM31376), various preliminary biochemical assays were per-
formed. During each step of the purification of the compound (carried out by Hamed Mosaei
Sejzi in DemurisTM), aliquots were taken to conduct parallel tests in vitro to verify that the
RNAP inhibition activity had not been lost (data not shown).
When it was discovered that DEM31376 had a different mass to Rifampicin (Rif) (822.94
g/mol) a transcription assay was performed to try to understand the effect of DEM31376 on
RNAP and its similarity and differences to Rif (see appendix for Rif control experiments), one
of the major antibiotics against prokaryotic RNAP (Fig. 6.3a).
E.coli RNAP core enzyme was pre-incubated with σ70 and a DNA fragment containing the
T7A1 promoter (a strong promoter of T7 bacteriophage), to allow the formation of the open
promoter complex (RPo). DEM31376 was added at a final concentration of 100, 10 and 1
µg/µL before and after RPo formation. Once the RPo was formed, all four NTPs were added
including α[32P]-UTP, and the transcription reaction was incubated at 37 °C for 10 min. A vis-
ible repression of RNA production by RNAP was observed at all concentrations of DEM31376
(Fig. 6.3a). In the absence of the compound (Fig. 6.3a Lanes 1 and 5) both abortive products
and full length RNA products were produced (Fig. 6.3a Lanes 1 and 5).
As increasing amounts of DEM31376 were added into the reactions before RPo formation
(Lanes 2-4), synthesis of both abortive products and full-length RNA was inhibited. Simi-
lar results were obtained when DEM31376 was added after RPo formation (see figure 6.3 a
lanes 6-8). This preliminary result suggested a different mechanism of action of DEM31376
compared to Rif, as the latter antibiotic causes a direct arrest of RNA after synthesis of small
transcripts, which, as shown in figure 6.3a, does not occur in the presence of DEM31376.
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Figure 5.2: Transcription assays with E.coli and T7 RNAP.
a) Transcription assay with E.coli RNAP. RNAP was incubated with T7A1 promoter DNA.
DEM31376 was added, before (Lanes 2-3-4) and after (Lanes 6-7-8) RPo formation, in de-
creasing amounts. The reactions proceeded in the presence of all four NTPs (25 µM ATP, GTP,
CTP, 5 µM UTP and α[32 P]-UTP) and were incubated for 10 min at 37 °C .
b) Transcription assay with T7 RNAP. RNAP was incubated with a short T7A1 promoter DNA.
DEM31376 was added, before (Lanes 2-3-4) and after (Lanes 5-6-7) RPo formation, in decreas-
ing amount. The reactions proceed in the presence of all four NTPs (25 µM ATP, GTP, CTP, 5
µM UTP and α[32 P]-UTP) and were incubated for 5 min at 37 °C . The reaction of both assays
were resolved in 20 % PAGE gel and analyzed using ImageQuant software. DEM= DEM31376,
Roff= run off (157nt), T= terminator (100 nt).
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In order to determine the specificity of the compound, an additional transcription assay was
carried out using T7 RNAP polymerase in place of E.coli RNAP (Figure 6.3b). T7 RNAP is
a single subunit RNAP structurally unrelated to the more complex multi−subunit RNA poly-
merases (Sousa et al., 1993). As before, the compound was added before and after T7 RNAP
RPo formation. H2O was used as control, and the reactions were carried out similarly to E.coli
transcription assay. DNA template was different, due to T7 RNAP propriety, and the incubation
time was inferior (the protocol is explained in detail in Material and Methods). From these
results (Figure6.3), it is clear that DEM31376 is a potent selective inhibitor of E.coli RNAP but
not of T7 RNA polymerase, meaning that DEM31376 has a strong inhibition selectivity.
5.3.2 NMR Data
During our in vitro assays, NMR (nuclear magnetic resonance) analyses were performed by
our collaborators in the chemistry department at Newcastle University, Dr. Corinne Wills, Dr.
Michael J. Hall and Andrew R. Tyler. All mass spectroscopy experiments were performed by
Dr. Joe Grey. NMR analysis revealed DEM31376-A contains an oxazoline structure, a chemical
heterocyclic structure containing one atom of nitrogen and one of oxygen, C3H5NO shown
in Figure 6.2. DEM31376 shows structural similarity with other compounds containing an
oxazoline ring such as Gobichelin A, Transvalencin Z, and Amychelin (Chen et al., 2013; Mukai
et al., 2006; Seyedsayamdost et al., 2011). These compounds, also produced by Actinobacteria,
feature a siderophores structure and exhibit anti-microbial activity.
Once the structure had been determined, molecule DEM31376/A was hypothesised to be a com-
pound known as Madurastatin C1 (Mazzei et al., 2012) illustrated in Figure6.2. Madurastatin
C1 is not known to inhibit bacterial RNAP. The strain that produce this compound is the same
that produce another antibiotic known as GE23077. For this reason a deep mass spectroscopy
was carried out by our collaborators. Figure 5.4 provided by Hamed Mosaei Sejzii, shows the
chromatogram obtained from Liquid Chromatography-mass spectrometry (LC-MS) at which
GE23077 was detected. GE23077 was known to inhibit transcription by unknown mechanism.
On the base of the data obtained, we decided to investigate the mode of action of these com-
pounds with several in vitro assays.
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NMR:          COSY             HMBC
DEM31376 structure
Figure 5.3: The proposed structure of DEM31367/A as determined by nuclear magnetic reso-
nance spectroscopy. The compound is formed mainly of an oxazoline ring (a chemical hetero-
cyclic structure containing one atom of nitrogen and one of oxygen); Correlation spectroscopy
(COSY) is showed in black and Heteronuclear multiple-bond correlation spectroscopy (HMBC)
is showed in red.
Figure 5.4: LC/MS performed on DEM31376 by Hamed Mosaei Sejzi
5.3.3 DEM31367 Targets Transcription Initiation During First Nucleotide
Addition and not During Chain Elongation
To gain a clearer understanding of how thise compounds work, and if its effects occur before
addition of the first nucleotide (e.g. like Lipiarmycin, described in section 1.2.3.3) or during the
elongation process (e.g. as Streptolydigin, described in section 1.2.3.2), two different assays
were performed.
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To investigate the possibility of inhibition during initial RNA synthesis, the effect of DEM31376
on the formation of a three nucleotide product by the RNAP holo-enzyme was determined.
An abortive transcription assay was used in which RNA synthesis at the T7A1 promoter was
initiated by the addition of a dinucleotide primer known as CpA. CpA anneals to position -1 to
+1 of the T7A1 DNA promoter region increasing the ability of the RNAP holo-enzyme to begin
synthesis of the RNA. In this case, radio-labelled α[32]P-UTP was added to permit the formation
of three nucleotide CpApU abortive product (Figure 6.4a). DEM31376 was added at the final
concentration of 100, 10, and 1 µg/mL before and after binding of the RNAP to the DNA. The
results indicate that DEM31376 (mixure of both, Madurastatin C1 and GE23077) inhibits the
formation of abortive products at the concentration of 100 µg/mL (Figure6.4 a, lanes 4 and 10).
Rifampicin at a final concentration of 100 µg/mL (Figure6.4, Lanes 3 and 9) was used as a
reference inhibitor as it is known that it inhibits transcription initiation after synthesis of initial
short RNA products (?). This preliminary analysis suggests that DEM31376 potentially has a
different target on E.coli RNAP compared to Rif.
Although DEM31367 was shown to inhibit transcription initiation, it is possible that it may also
inhibit elongation. To determine the possibility of inhibition during chain elongation an assay
was performed in which a 20 mer RNA product (EC20) was synthesised before addition of
DEM31376. The elongation complex (EC) was formed by mixing E. coli RNAP holo-enzyme,
biotinylated T7A1 template DNA and the tetra-nucleotide CpApUpC. By adding CTP/ATP and
GTP nucleotides, the polymerase was able to synthesise 20-mer RNA (Figure 6.4b). α32P-GTP
was used to been incorporated during EC20 formation. After formation of the EC20, all NTPs
were added in the presence or absence of DEM31376. The effect of DEM31376 on RNAP
during elongation was determined by the ability of RNAP to synthesise the full length product
(Roff and T) from EC20. As shown in Figure 6.4b, no inhibition was observed during elongation
in the presence of DEM31376.
In conclusion, DEM31376 inhibits RNAP during initiation of transcription but not during elon-
gation. Even though this effect is similar to Rif, there appears to be a difference in terms of
the mode of action. To elucidate this alternative mode of action, further in vitro assays were
performed.
CHAPTER 5. DEM31376 49
NT-DNA atacttacagccAtcgagagggac
T-DNA atggctattcgccgtgtccctctc
EC20
T
Roff
+N
TP
s
+D
M
SO
+R
IF
 +DEM
a)                                                                                 b) 
Free NTPs
CpAU*
before RPo
_
+DEM
D
M
SO
R
IF
after RPo
_
+DEM
D
M
SO
R
IF
1    2 3    4  5   6   7  8   9    10   11  12
1       2       3       4       5      6       7
DEM31376 
added before Rpo 
DEM31376 added 
after Rpo 
RNAP + σ70
(1X TB)
DEM31376
DNA*
RNAP + σ70
(1X TB)
DEM31376
DNA*
RNA20  CAUCGAGAGGG
RNA         AUCGAGAGGGACACGGCGAA
T-DNA CGGTAGCTCTCCCTGTGCCGCTTATCGGTA
NT-DNA GCCATCGAGAGGGACACGGCGAATAGCCAT
T-DNA
bead
RNA 
polymerase 
+NTPs
(+RIF) (+DEM31376) 
NT-DNA
EC20
AU* 
C
Figure 5.5: Inhibition of abortive transcript synthesis and transcription elongation.
a) Abortive transcription. Lanes 1 the 7 (no DEM31376) and 2 and 8 (DMSO) act as negative
controls. Rif was used as a reference inhibitor with a final concentration of 100 µg/mL (lanes
3 and 9). To determine the exact mechanism of action, DEM31376 was added in decreasing
amounts, as illustrated in lanes 4 to 6 and 10 to 12. Each reaction was carried out using
CpA dinucleotide and α[32P]-UTP, with a DNA template containing the T7A1 promoter. The
products were resolved on 33% denaturating polyacrylamide gel.
b) Transcption elongation assay. RNAP was walked to form the elongation complex of 20-mer
elongation complex (EC20) by adding ATP, CTP and radiolabelled α32P-GTP after initiation
with the tetra-nucleotide CpApUpC (lane1). The 26-mer band above the 20-mer is due to a
small amount of misincorporation by RNAP. In lane 2, NTPs were added at final concentration
of 20 µM and a decreasing concentration of DEM31376 was used (lane 5-6-7). The results show
that elongation was not affected by DEM31376. The products were resolved on denaturating
20% polyacrylamide gel.
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5.3.4 DEM31376 does not Inhibit Initial Open Complex Formation
In the previous section it was shown that DEM31376 acts during the first steps of RNA synthe-
sis, but not during transcription elongation. Whilst the mechanism of action is not known, it is
possible that DEM31376 alters the initial complex formed between RNAP and the DNA during
transcription initiation.
Hypothetically, an interaction between DEM31376 and the RNAP holo-enzyme could occur
during recognition of the promoter and formation of the RNAP/DNA complex. For example,
the antibiotic Lipiarmycin blocks the formation of the initial RPo complex, as shown by elec-
trophoretic mobility shift assay (EMSA) in Tupin et al. (2010b).
To test the interaction between DEM31376 and RNAP/DNA complex, the same EMSA assay
was performed (Fig. 5.6) using E. coli RNAP holo-enzyme and a short radiolabelled DNA tem-
plate (a modified T7A1 promoter, see section 3.2). The compound was added before and after
RNAP/DNA complex formation and the template DNA segment was radiolabelled to ensure
that the fully assembled complexes were visible. Rif was used as a control, as it binds close
to the active center of the polymerase without destroying the RNAP/DNA complex (Lanes 14
and 15). As positive control, a compound, taken from the DemurisTM collection, and discov-
ered to have the ability to inhibit the formation of the RNAP/DNA complexes by intercalating
the DNA, was used. The intercalation of the DNA prevents the assembly of the RNAP/DNA
complex.
The reactions were set up as shown in Figure 5.6a. As shown in Lanes 9 and 10, DEM31367
does not prevent the assembly of the RNAP/DNA complexes, neither does it disrupt the com-
plexes once formed. This is the same as with Rif (Lanes 4 and 5), showing a similarity between
the two compounds even thought they must have a different mode of action (see section 4.3.2)
5.3.5 Kinetics of Transcription Inhibition by DEM31376
During the screening process, determining the amount of a compound required for maximal ef-
fect is fundamental in determining its usefulness as a potential drug. For this reason, finding the
half-maximal inhibitory concentration (IC50) is crucial. In light of this, and after analysing the
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Figure 5.6: Electrophoretic mobility shift assay (EMSA) of DEM31376/RNAP complex.
(a) The scheme represents the order in which the reactions in lanes 4/5, 9/10 and 14/15 in (b)
were performed. In lanes 1, 6 and 11 is present only the free radio-labelled DNA. Lanes 3 shows
the complex RNAP/DNA in presence of Rif (used as positive control), in Lanes 8 in presence of
DEM31376 and in Lanes 14 with the negative control when each compound was added before
the DNA. In Lanes 5, 10 and 15 Rif/DEM31376/ and the negative control were added after
the DNA. Each sample was loaded in 4% Native PAGE immediately after added 3 µL of stop
reaction containing 25 µg/mL of heparin. Radioactive bands were analysed using ImageQuant
software.
data obtained so far, the IC50 value was calculated using the abortive assay and an exponential
dilution of DEM31376.
The experiment was carried out as previously in abortive assays, using 10 µM of unlabelled
UTP, α[32] P-UTP and decreasing amount of DEM31376. The products were separated on a
33% denaturing polyacrylamide gel and analysed using ImageQuant and Sigma Plot software.
The IC50 value was calculated in the presence of 10µM of UTP and a titration of DEM31367
was used.
To determine if there is any competition with NTPs the abortive assay was repeated, this time
using 100 times the amount of UTP (1mM instead of 10µM) with the same exponentially de-
creasing amount of DEM31376. DEM31376 was added after RPo formation but before UTP
addition. The results were analysed using ImageQuant software. The new IC50 value is only
half of obtained using the original NTP concentration, meaning that there is no competition
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between DEM31376 and NTP uptake (Fig.4.7b).
Free NTPs
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Free NTPs
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_ DEM31376
a)                                                       b)
IC50 (UTP 10μM)= 1/64 IC50 (UTP 10μM)= 1/128
1μL 1/512μL 1μL 1/512μL
Figure 5.7: DEM31376 IC50 calculated with a) 10 µM and b) 1 mM of un-labelled UTP
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The abortive assay was once again repeated using 25 µM and 250 µM of un-labelled UTP and
1/4 of the original sample of DEM31376, as this concentration is higher than the IC50, meaning
that the concentration of DEM31376 is at saturation point. The compound was added before
and after RPo formation, and the percentage of inhibition was calculated. The results from this
assay shown in Figure 5.8 reveal that there is no change in terms of inhibition when DEM31376
is present in different concentration of NTP. When the inhibition of DEM31376 was tested
before RPo formation, it corresponded to approximately 90% (with both 25 or 250 µM of un-
labelled UTP). The same occurred when DEM31376 was added after RPo formation. The level
of inhibition observed in this case was roughly 85% with both 25 or 250 µM of un-labelled UTP.
Changing the NTP concentration had no effect on the percentage of inhibition. These results
together suggest that there is not competition between DEM31376 and NTP uptake.
- +    - +     - +    - + 
250       25       250     25 
before Rpo          after Rpo
90         91         86         85
UTP (μM)
DEM31376
%  Inhibition
CpAU
Figure 5.8: Abortive assay od DEM31376 by using different concentration of UTP (25 and 250
µM)
After the IC50 value is known, the effect of DEM31376 on transcription elongation was re-
examined using a concentration of the compound higher than the IC50 value. The elongation as-
say described previously (see Material and Methods) was repeated with or without DEM31376.
In this experiment, samples were taken at different time points (0, 5, 10, 30, 60, 120, 300,
600 sec) to assess the trend of inhibition over time. The data were analysed using ImageQuant
software. Run-off (Roff, approximately 157 nt length from +1), Terminator (T, approximately
100) and EC20 were investigated as shown in figure 4.9. Analysis of the data shows that there
is no substantial difference in transcription in the presence of DEM31376. Therefore we can
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conclude DEM313476 is not interrupting RNA synthesis when RNAP is in elongation phase
(Figure 5.9)
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Figure 5.9: Inhibition of elongation by DEM31376.
(a) Elongation complex EC20 was used as the start point for this elongation assay. EC26 is due
to misincorporation by RNAP. The reactions were stopped at different time points (0, 10, 30,
60, 120, 300, 600 sec) and resolved by denaturing PAGE on a 20% gel before visualizing by
phosphorimaging. Quantification was performed using ImageQuant an SigmaPlot. The Roff,
T, and EC20 behaviour was schemed in (b), (c) and (d) respectively. The concentration of the
compound used was 0.025 mg/mL.
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5.3.6 Target of DEM31376
The results obtained so far clearly demonstrate that DEM31376 targets transcription during
initiation. The step was to understand how DEM31376 and RNAP interact. To this end, an
additional assay was performed using a different primer at the beginning of RNA synthesis. A
primer, such as CpA, is defined as a short nucleotide sequence that causes a major increase in
the amount of new RNA chain synthesis. The higher the number of primers present, the higher
the number of RNA chains is synthesized. In previous experiments, the CpA di-nucleotide
primer was used. During the transcription reaction, CpA binds the DNA at the position cor-
responding to -1 and +1 from the synthesis start site. In this new experiment, CpApUpC was
used as the initial primer. CpApUpC is a tetra-nucleotide, that binds at position -1 to +3 on the
DNA. Adding this tetra-nucleotide reduces the space available in the active center, furthermore
CpApUpC binds more tightly than CpA and can compete better with the compound.
Two different assays were carried out using E.coli RNAP holoenzyme, a DNA template with
the T7A1 promoter sequence and the CpA (1 mM) or CpApUpC (200 µM) primer. Depend-
ing on which primer was used, either α[32 P]UTP or α[32 P]GTP was also added. In these
two experiments, DEM31376 was added at different points during the reactions (see schematic
representation in Figure 5.10). Each reaction was incubated at 37°C for 4 min and the transcrip-
tion products were resolved on a 33% denaturating PAGE gel, and visualised with ImageQuant
software and analysed using SigmaPlot.
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Figure 5.10: Transcription initiation carried out Cpa (1 µM) and CpApUpC (200 µM).
a) Experimental setup 1. DEM31367 compound (hereafter referred to as DEM) was added to
the open complex (Rpo). After the binding between the compound and the RPo, the Cpa primer
was added along with radiolabelled UTP 2. The experimental setup differed slightly to that of
1. The Rpo was formed then the short CpA primer added. After the binding of the CpA primer
to the template DNA at position +1, the compound was added along with radiolabelled UTP.
3. and 4. The experimental setups described in 1 and 2 were repeated using a longer primer,
CpApUpC, that has stronger binding to the +1 T7A1-DNA site due to the longer primer length
compared to the CpA primer. The same experimental setup for 1 and 2 was used in 3 and 4
respectively using the CpApUpC primer and radiolabelled GTP to label the RNA.
b) [Left] Transcription initiation using the CpA primer and radiolabeled UTP. The products
were loaded on a 33% PAGE gel and analysed using ImageQuant software. The lane indicated
by the asterisk contains the control reaction performed in the absence of the compound where
only CpA and radiolabeled UTP were added to the RPo. The top band represents the CpApU
product produced after incubation at 37 °C The bottom bigger band shows the unincorporated
radiolabelled UTP in the reaction. Lane 1 shows the products produced from the reaction de-
scribed in a 1. Lane 2 shows the products produced from the reaction described in a 2. The
amount of CpA product produced in the reaction relative to the control is shown below the gel.
[Right] Transcription initiation using the CpApUpC primer and radiolabeled GTP. The lane in-
dicated by the asterisk contains the control reaction performed in the absence of the compound
where only CpApUpC and radiolabeled GTP were added to the RPo. The top band represents
the CpApUpCpG product produced after incubation at 37 °C . The bottom bigger band shows
the unincorporated radiolabelled GTP in the reaction. Lane 3 shows the products produced from
the reaction described in a 3. Lane 4 shows the products produced from the reaction described
in a 4. The amount of CpAUpCpG product produced in the reaction relative to the control is
shown below the gel. Each sample was loaded in 33% gel and analyzed using ImageQuant
software.
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In all reactions, RNAP was combined with σ70 before incubation with promoter DNA to form
the open complex. As shown in Fig. 5.10 a, DEM31376 was added before CpA α[32 P]UTP
(Lanes 1) or after (Lane 2). In Lanes 3 and 4 represent the second assay, which uses CpApUpC
primer (200 µM) with the same order of assembly as lanes 1 and 2. The second part of the
image (b) shows the results obtained. Lane 1 shows 34% of activity compared with the lane
without compound (where 100% of activity was detectable), but this differs when the order
of the reaction assembly was reversed (lanes 2). The same trend was noticed in presence of
CpApUpC, a stronger inhibition was revealed when the compound was added before the pres-
ence of the primer. These data indicate that DEM31367 strongly inhibits the the addition of the
first nucleotide as clearly shows in Figure 5.10b Lanes 1 and 3.
5.4 Discussion and Conclusion
Given the results presented in this chapter, it is reasonable to conclude that DEM31376 (mixture
Madurastatin C1 and GE23077) acts by specifically inhibiting addition of the first nucleotide
during transcription initiation (Fig.5.6a) and that the production of the full length of RNA is not
a target for this compound (Fig. 5.4).
DEM31376 corresponds to Madurastatin C1, a compound produced by Actinomadura sp. and
not well studied in terms of inhibition against any RNAP (Harada et al., 2004). During our
in vitro tests our collaborators in DemurisTM discovered that the same strain that produces
Madurastatin C1 can also produce a second bioactive metabolite known as GE23077 which
could not be detected by HPLC and high resolution mass spectrometry. Figure 5.4, given from
Hamed Mosaei Sejzi, shows the chromatogram obtained from Liquid chromatography–mass
spectrometry (LC-MS) at which GE23077 was detected.
Based on our data, and knowing from the literature that the IC50 of GE23077 against wt E.coli
RNAP is particularly low (IC50 40 nM) (Zhang et al., 2014) we can assume that GE23077 works
by inhibiting abortive synthesis as we demonstrated in this chapter. Recently, after our work,
a paper detailing the mode of action appeared that confirmed our results (Zhang et al., 2014).
GE23077 binds bacterial RNA polymerase, preventing the binding of initiating nucleotides and
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inhibiting the transcription initiation but not the elongation process (as shown demonstrated
in this chapter). GE23077 inhibits nucleotide addition during transcription initiation without
destroying the initial RNAP/DNA complex, fully consistent with our data (Zhang et al., 2014).
For the importance of madurastatin C1 molecule, our collaborators in DemurisTM and in the
Chemistry department are currently trying to synthesize the proposed molecule because there
are no studies related with RNAP and regarding its mode of action.
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Chapter 6
DEM10430
6.1 Introduction
The isolation of compound DEM10430 was carried out by our collaborators in the DemurisTM
lab, mainly by Hamed Mosaei Sejzi. Based on the 16S rRNA gene sequence (1405 bp), the
strain DEM10430 share 99.5% similarity to Streptomyces djakartensis, with a difference of
only 7 bp. The DEM10430 strain was cultivated for 6 days in GYM medium (4 g/L yeast
extract, 10 g/L malt extract, 4 g/L glucose, 10 mL/L glycerol, adjusted to pH 7) at 30 °C.
The cell free supernatant was subjected to high speed centrifugation and mixed with Amberlite
resin beads (ion exchange resins and polymeric adsorbent) to bind the DEM10430 compound.
Methanol extraction followed by reverse phase Biotage HPLC (C18) was used to further purify.
Finally, the compound under HPLC step was performed in order to obtain as pure a compound
as possible (Figure 6.1 a)
From the DEM10430 producing strain, more than hundreds secondary metabolites were ob-
tained and tested for antimicrobial activity using a zone of inhibition assay in DemurisTM lab,
and those active in these tests were then tested in our lab. After our preliminary test in vitro
to verify the activity against RNAP, only one compound was of particular interest and, after
purification as shown in Figure 6.1 it was identified as potential interesting compound.
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Figure 6.1: An overview of the key steps involved in the isolation and identification of
DEM10430. The DEM10430 strain was grown at 30°C for 6 days in GYM media. Then, the
culture was mixed with non-ionic resin (Amberlile XAD-16N) used for adsorption of organic
substances from aqueous systems and polar solvents. The compound activity was monitored
using an in vitro assay against E.coli RNAP. The active peak was analysed by reversed phase
chromatography HPLC (C18).
6.2 Aims
DEM10430 has been shown to inhibit RNAP in vivo in DemurisTM lab by Hamed Mosaei Sejzi.
The aim of this study was to clarify the mechanism of this inhibitory effect in vitro transcription
and to identify any possible interactions with E.coli RNAP.
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6.3 Results
6.3.1 DEM10430 blocks RNA synthesis during elongation.
In order to explore the mechanism the action of DEM10430, a variety of different in vitro tests
were performed. First, as it was shown that DEM10430 blocks RNA synthesis in vivo, a possible
interaction with RNAP was investigated using an in vitro approach in our lab. In particular, we
were interested to see if DEM10430 inhibited RNAP during the first stages of transcription.
Briefly, transcription was carried out in the presence of the three nucleotides instead of all full
set of NTPs, enabling analysis of the small transcript produced during the very first stage of tran-
scription. The experiment was performed using RNAP holoenzyme incubated with T7A1 DNA
promoter and CpA was added with CTP, GTP and radiolabeled α32P-UTP to obtain abortive
transcription (see section Material e Methods 3.2). RNA synthesis was allowed to proceed for 2
min at 37°C in presence and absence of DEM10430 (added after DNA). RIF and DMSO were
used as controls (Figure6.2 a).
At this point of the project, two main fractions of the same compound were available to test,
fraction 30 and fraction 28. Both were obtained from the same HLPC Actinomycetes purifica-
tion. Both compounds were tested in various in vitro assay, in order to determine which fraction
was more active against E. coli RNAP (Figure 6.2 and data not shown).
In abortive assays, using only three of the four nucleotides, short transcript products ran as 2
separate bands (Figure 6.2 b). In Lanes 2 and 3, DMSO and RIF were present as controls. Both
fraction of DEM10430 were tested in decreasing amounts (Figure6.2 line 4 to 7) and added
after RPo formation. As shown by the synthesis of the short transcript products (Lanes 4-7),
DEM10430 did not inhibit the initiation of transcription, meaning that incorporation of the ini-
tial nucleotides was not a target of the compound.
In addition to the abortive assay, a second transcription assay, an elongation assay, was per-
formed. In this experiment all four NTPs were provided to test a potential interaction during
chain elongation (Figure 6.2 c). Briefly, the holo-RNAP was pre-incubated with T7A1 promoter
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before the addiction of DEM10430. The reaction was kept at room temperature (RT) for less
than 5 minutes (min), followed by NTPs. The experiment is described in more detail in sec-
tion Material and Methods. Synthesis of the RNA was allowed to proceed for 10 min at 37°C
and the reaction was stopped by adding stop buffer containing formamide, the products were
resolved by denaturing 20% PAGE (8 M Urea).
The full transcription assay showed the effect of DEM10430 on RNAP during RNA synthesis
(Figure 6.2 c). As in the previous experiment, DMSO was used as control (Lane 2 Figure 6.2
c). In contrast to the abortive assay, in this second assay there was a clearly visible effect of
DEM10430 on the synthesis of RNA by RNAP (Lane 3, asterisks).
Forward primer binding side
+1
- 10
Reverse primer binding side
- 35
mRNA  synthesis
ggtcgactctagaggatcgctataaca[...]attgacttaaagtctaacctataggatactt
acagccAtcgagagggacacggcgaatagccatcccaatcgacaccggggtccgggatctgga
tctggatcgctaataacaggcctgctggtaatcgcaggcctttttatttggatccccgggtac
cgagctcgaattcactggccgtcgttttacaacgtcg
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Figure 6.2: DEM10430: Abortive and elongation assays.
(a) T7A1 DNA template sequence displaying oligonucleotide binding sites, -35 and -10 pro-
moter elements and transcriptional start site +1. (b) Results of transcription experiments as-
sessing the effects of DEM10430 on abortive initiation. (c) Transcription assays with E. coli
RNAP. Inhibition by DEM10430 is dependant on the transcript sequence. The DNA template
used contained the T7A1 promoter. Each sample was loaded onto 20% denaturing PAGE gel
and analysed using ImageQuant software.
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The results suggest that DEM10430 does not inhibit the formation of abortive products (short
mRNA species, produced before the transcription complex leaves the promoter), as RIF did.
Instead, it appears to inhibit the formation of full-length products by blocking RNA synthesis
during transcription elongation.
The above experiments were all performed using an assay that assesses the effects of DEM10430
after formation of the open complex (RPo).
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Figure 6.3: DEM10430 Potassium permanganate (KMnO4) footprint.
Potassium permanganate (KMnO4) footprint probing of the T7A1-promoter complexes formed
by the wt RNAP in the presence of DEM10430 at two different time point, 30sec (Lanes 1-4)
and 1 min (Lanes 4 to 8). DNA was labelled by 32 P at the 5’ end of NON-template strand
(Lane 9 without KMnO4 treatment, Lanes 1 and 5 adding KMnO4). DNA in complex with only
RNAP is shown in Lanes 2 and 6, and DEM10430 in complex with DNA and RNAP is shown
in Lanes 3 and 7.
In order to determine if DEM10430 was able to prevent the formation of the open complex, a
potassium permanganate footprinting (KMnO4) assay was performed. This method is based on
the selective oxidation to the thymines present at the open (melted) DNA regions, modified by
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KMnO4 and subsequently cleaved by treatment with piperidine. Briefly, the KMnO4 experiment
was carried out by mixing 10 pmol of RNAP with 40 pmol of σ70, then 2 µL of DEM10430 was
added. DNA radio labelled at 5’ end of the non-template strand was added and after 10 min
of incubation at 37 °C, KMnO4 was added (20 mM final concentration) for either 30 sec or 1
min. After chloroform extraction, DNA was cleaved by 10% piperidine. Followed by another
chloroform-ethanol extraction, the final pellet was dissolved in loading buffer and resolved on
a 6% denaturing polyacrylamide gel and analysed.
By comparing Lanes 2 and 3 (30 sec of incubation with KMnO4) and 6 and 7 (1 min of incuba-
tion with KMnO4) in Figure 6.3 the cleavage pattern is the same in the presence and absence of
DEM10430, allowing us to conclude the compound does not inhibit open complex formation.
A different compound known to destroy the open complex was used as control, and in Lanes 4
and 8 can be seen by the absence of the bands.
Based on the earlier results showing the inhibitory effect of DEM10430 on RNAP during tran-
scription elongation and after verifying by KMnO4 footprinting that the open complex was
not involved in the inhibition, more analyses were required to further understand the effect of
DEM10430.
6.3.2 DEM10430 blocks transcription on specific DNA template sequences
During the elongation, in presence of compound DEM10430, pausing was observed (see fig
7.2b). To investigate this further, and to pin-point exactly which sequence was involved, an
elongation assay was developed. An elongation assay was created in which RNAP was halted
on the T7A1 DNA template at positions +20, +34, and +44 with respect to +1 to be start site
(Figure 6.4 a). These were named EC20, EC34 and EC44, respectively. After the RNAP was
halted, DEM10430 was added and transcription elongation was restarted by the addition of
all four NTPs (Figure 6.4 b). These specific ECs were chosen based on the observation that
the presence of DEM10430 during transcription elongation causes the RNAP to pause at sites
approximately between +20 and +50 on the DNA template. Each elongation complex (EC20,
EC34, EC44) was prepared using wt E.coli RNAP in the presence of strong T7A1 promoter and
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an incomplete set of NTPs with plus α-[32P]-GTP, which would stall the RNAP after synthesis
of 20, 34 and 44 nucleotide-long RNAs. All ECs were immobilized on streptavidin coated
beads via a biotin tag present on the template DNA. This allowed detection of only radiolabelled
RNA in complex with RNAP. After the formation of the ECs, each reaction was incubated (with
DEM10430) at 37°C for 10 min in the presence of all four NTPs to permit the transcription until
the end of the template (Figure 6.4b). The reactions were stopped and resolved on a denaturing
23% PAGE gel. The full protocol is explain in details in section Material Method. As can be
seen in Fig. 6.4) the stalled ECs, with transcripts of a known length, were used to determine the
pause site. Each stalled EC is shown in Lane 1 (EC20), Lane 3 (EC34) and Lane 5 (EC44). A
full length was used as a marker along with full length transcription using all NTPs (Lanes 7).
Lanes 2, 4, and 6 show RNA synthesis from the EC in the presence of DEM10430. Analysis of
RNA synthesis from the EC pause sites used in this experiment reveals that, RNAP blocks/pause
at positions +33; +39 and between +45/+46 were found to correspond to TC, CC and TC base
pairs using the DNA promoter, sequence visible in Fig. 6.4a.
The above findings suggest that the pauses observed during transcription elongation occur at
specific sequences in the DNA template. In addition, from the gel above, is noted that the
compound acts depending how close is to the RNAP/DNA complex. When the transcription
starts from EC20, the main band (+39, 2nd Lane) is well detectable as compared to the marker
(7th Lane). A different trend occurs when the transcription starts from +34mer, the ’pause’ at
+39 has lower intensity (4th Lane). The same trend occurs when the transcription starts at +44
and the band at +45 is almost absent. By these results can be said that the compound DEM10430
is not able to destroy a complex RNA/DNA that is already formed.
6.3.3 Echinomycin
At this point of the project, our collaborators in Demuris calculated the mass of DEM10430.
Based on the data obtained by mass spectra, DEM10430 has a mass of 1100.4208. The online
tool ‘Dictionary of Natural Products’ was used to determine if there were any existing com-
pounds with the same mass. It was found that DEM10430 corresponds to the antibiotic known
as Echinomycin/Quinomycin A (QN, C51H64N12O12S2) (Figure 5.6 c).
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Sequence of T7A1 promoter
tattgacttaaagtctaacctataggatacttacagccAtcgagagggAc
acggcgaatagccatcccaaTcgacaCcggggTccgggatctggatct
+1-10-35 +20
+33 +39 +45
EC20
33
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45/6
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ECs
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Figure 6.4: DEM10430 blocks transcription in sequence specific manner.
a) T7A1 NT-template DNA sequence with region -35 and -10 of the promoter; transcriptional
start site (+1) and all three regions involved with DEM10430 binding (+33;+39,+45/6) high-
lighted. +20 indicates the position from which transcription elongation is started. template
DNA (not shown) has biotin tag.
b) Elongation in vitro. EC20/EC34 and EC44 were incubated in presence of NTPs and
DEM10430 (1 µL) for 10 min at 37 °C before being stopped by addition of an equal vol-
ume of stop buffer containing formamide. The products were separate on 23% denaturing gel
and the radioactive bands were analyzed by ImageQuant Software.
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(c)   Echinomycin structure 
(a)    High resolution spectroscopy                                              (b)    Echinomycin/DNA 
Figure 6.5: (a) Mass spectra of DEM10430. Hight peak shown is the compound tested.
(b) Structure of two Echinomycin molecules, in red, intercalated into the DNA (PBD:2AC)
(c)Echinomycin Structure
Echinomycin was discovered in 1957 as a compound produced by Streptomyces echinatus (Cor-
baz et al., 1957). Echinomycin is a member of the quinoxaline group of antibiotics, these antibi-
otics contain a ring complex formed by a benzene and a pyrazine ring. These rings allows Echi-
nomycin to bind the DNA (Jarikote et al., 2011), but not RNA (Waring and Wakelin, 1974a), by
bis-intercalation. A bis-intercalating compound contains two units, usually cationic, separated
by a spacer chain that must to be long enough to allow double binding of the DNA (Waring and
Wakelin, 1974b; Ughetto et al., 1985; Watanabe et al., 2006) (Figure. 5.6). Echinomycin was
originally found to be a powerful antibacterial agent, especially against Gram-negative bacteria
and it was found to be effective against RNA polymerase (Gause et al., 1968; Mackedonski,
1969). The discovery of its function as a DNA bis-intercalator, suggests that Echinomycin is
responsible of causing a block of RNA synthesis. Further biological effects of Echinomycin
were found as, for example, as antitumor activity (Brana et al., 2001).
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6.3.4 DEM10430 has a strong binding with the DNA
According to the DEM10430/Echinomycin specificity discovered in section 5.3.2, a binding
specificity for CG was found, consequently blocking the RNAP 1 bp upstream the compound.
We then proceeded by investigating how strong was the binding between Echinomycin and
RNAP. For this reason an assay was performed and was carried out in the elongation phase
(Figure 6.6). A 20-mer transcript was created (see Material and Methods) and after taking
EC20 as control reaction (Lane 1), two different aliquots were used for run off transcription.
The first aliquot of EC20 was supplied with all NTPs (Lane 2) whist the second was provided
with NTPs and DEM10430 (Lane 3). Both reactions were stopped using formamide loading
dye. As previously shown, the main blockage (+39) was visible as distinct bands in the reaction
where DEM10430 was present (Figure6.6). In addition, a third aliquot was taken (Lane 4) to
evaluate if DEM was still present and bound with DNA after washing 6 times with 1X TB
(without MgCl2) (Lane 4). If DEM10430 easily dissociates from the DNA, the E.coli RNAP
should be able to transcribe the full length of the template. The gel shows that the main band
(+39) is still present, even after washing the reaction. The final step (Lane 5) was carried out in
parallel to establish whether or not DEM10430 would be able to bind the DNA in the event that
the washing process had removed it from the DNA. Therefore, a final aliquot was taken after
the washing process to which DEM10430 and NTPs were added (Lane 5).
The bond formed between DEM10430 and DNA is strong, as the compound was not removed
by consecutive washes (Lane 3) or by the transcribing RNAP (Lane 4) This means that RNAP
cannot demolish the DEM10430:DNA interaction when DEM10430 is already bound to the
DNA.
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Figure 6.6: [Left] Elongation of Echinomycin bisintercalator. [Right] scheme of DEM10430
elongation followed by several washes
6.4 Discussion and Conclusion
DEM10430, from all the metabolites obtained from DemurisTM, was the first compound found
to be able to intercalate into the DNA. With in vitro assays it was showed that its intercalation is
base specific, in particular at CG sequences, consequently blocks RNAP (Sato et al., 2013). Our
results are consistent with what was found in literature, namely that RNAP stops 1 bp upstream
the compound binding. Moreover, we observed that inhibition occurs only during elongation
and not only during the first phases of the transcription, which consist with the nature of being
DNA intercalate.
In conclusion, Echinomycin has a strong sequence specific binding activity. This activity blocks
RNAP 1 bp upstream of the drug binding site. Furthermore, we demonstrate that RNAP is not
able to remove bound Echinomycin molecules. As DEM10430 only interacts with downstream
DNA, further experiments could be carrying out to investigate in deep interactions between
RNAP and Echinomycin compound.
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Chapter 7
DEM30355B1 and B2
7.1 Introduction: Isolation and Purification
The DEM30355 strain was isolated from an Amycolatopsis strain collected from the Atakama
hyper-arid desert. Bioassay-guided fractionation, carried out by our collaborators in DemurisT M,
revealed the presence of three structurally diverse antibiotics produced by the same strain, which
were named DEM30355/A/ B1/ C. These three compounds, when tested, exhibited different in-
hibitory properties.
The structure of the antibiotic DEM30355/A, elucidated via X-ray crystallography and NMR,
is a novel tricyclic and partially aromatic compound. DEM30355/B1 is a precursor of the
Ansamycin type of antibiotics, known as Kanglemycin A, which was first isolated by Wang
et al. (1988). The DEM30355/C was identified as Vancoresmycin (Hopmann et al., 2002) via
tandem mass spectroscopy.
All the preliminary processes of isolation and purification of these compounds (Figure 7.1) were
carried out by our collaborators in DemurisTM lab, mainly by Dr. Bernhard Kepplinger. The
DEM30355 strain, was grown in GYMG media (4 g/L yeast extract, 10 g/L malt extract, 4 g/L
glucose, 10 mL/L glycerol, adjusted to pH 7). 500 L of cell free supernatant was collected and
10 kg of Aberlites XAD-16 beads were added to absorb all ionic species. The resin was then
filtered and the compounds eluted with Methanol, which was removed in a stepwise method by
reducing the pressure to give an aqueous extract. After a further extraction with Ethyl Acetate,
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the supernatant containing the compounds was loaded into a Biotage SNAP chromatography
cartridge to obtain a single peak containing the antibiotic of interest. These antibiotics were
further purified with gel permeation chromatography using the Biotage (C-18) Isolera. All
three fractions were collected and analysed by HPLC separately. Based on our preliminary in
vitro transcription assays DEM30355/B1 was chosen for further characterizations.
HPLC analysis, revealed that the B1 compound was subject to degradation during the pu-
rification process. A second series of analysis and purification was carried out to acquire
the second molecule derived from degradation of B1. The molecule obtained was named
as DEM30355/B2, and the yield was high enough to be used in in vitro experiments. Our
collaborators in the DemurisTM lab determined the mechanism as to how the degradation of
DEM30355/B1 to DEM30355/B2 occurs. This mechanism imply a non-enzymatic degradation
found to correspond an initial oxidative cyclisation followed by hydrolysis, and the final product
is shown in (Figure 7.1c).
The DEM30355/B1 peak obtained by mass spectrometry gave a mass equivalent to 1041.4186
Da. The online tool ‘Dictionary of Natural Products’ was then used to determine if there were
any existing compounds with the same mass. It was found that B1 has a similar mass to a
compound known as Ornipressin, a vasoconstrictor active against eukaryotic cells, but not
against any bacterial cells and not produced by any Amycolatopsis strains. This means that,
although DEM30355/B1 has a similar mass to Ornipressin, it is not the same compound. Due
to this discovery, DEM30355/B1 has the potential to be a novel antibiotic for use in treating
infection by TB. The peak obtained for DEM30355/B2 by mass spectrometry gave a mass
that corresponds to 981.9387 Da and this was found to be identical to a compound known as
Kanglemycin A (C50H63NO19 ∗MeOH), an antibiotic isolated from Actinomycetes and active
against Gram-positive bacteria. Since Kanglemycin A has a similar mass and characteristics to
DEM30355/B2, the latter was theorized to be structurally identical to it (Figure 7.1 b).
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Figure 7.1: Purification and structure of DEM30355.
a) Schematic of the purification procedure schematized was used for all three compounds. 500
L of media was used to grow the Amycolatopsis strain. After absorption of every secondary
metabolite by Amberlie resin (10 kg), the solution was elute in Methanol. After evaporation of
Methanol, the remaining extract was acidified (pH 4) and extracted by Ethyl acetate. Subsequent
HPLC gave a final purity of DEM30355 B of >95%.
b) Structure of DEM30355 B1 (mass 1041.42) which degrades in DEM30355 B hypothetically
(mass 981.40) from an initial oxidative cyclisation followed by a hydrolysis.
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7.2 Results
7.2.1 Bacterial RNAP Specificity of DEM30355-B1/B2 Inhibition
Single and multi-subunit RNAPs have different modes of action during the initiation of tran-
scription. To test the possibility of inhibition during transcription initiation by compounds
DEM30355 B1 and B2 against Gram-negative RNAP (wt E. coli), Gram-positive RNAP (B.
subtilis) and a single subunit RNAP (T7 RNAP), an assay of transcription initiation was carried
out. Transcription was initiated on the T7A1 promoter DNA template using the dinucleotide
CpA and either the E. coli holoenzyme containing σ70, the B. subtilis holo enzyme containing
σA, or T7 RNAP was used. All four NTPs were added to the reaction along with radiolabeled
UTP to monitor the production of the transcripts. Each transcription reaction was incubated
at 37 °C for 10 mins, (or 5 min for T7 RNAP) and the products resolved by denaturing 20%
PAGE (8 M Urea), revealed by PhosphorImaging (GE Healthcare) and analyzed using Image-
Quant software (GE Healthcare). H2O was used as a negative control and Rif as a positive
control as it blocks transcription after the synthesis of 3 nts of RNA. One reaction was also
carried out in the presence of DMSO alone, as Rif is dissolved in DMSO. For the reactions
with T7 RNAP, the Rif and DMSO controls were not used due to the increase in transcription
observed in the presence of DMSO (not shown).
With E.coli RNAP, the full length transcript was synthesised in the presence of both negative
controls, as shown by the production of abortive and run off (157nt) products as expected (Fig-
ure 7.2 a). In the presence of Rif, only short RNA products were observed, consistent with its
known inhibitory activity. In the presence of the DEM30355 B1/2 compounds, a similar inhibi-
tion to that of Rif was detected. Production of the full length transcript was abolished and only
the abortive products were visible (Figure7.2 a lanes 6 to 11). This suggests that DEM30355
blocks transcription by E. coli RNAP during initiation as confirming that the compound belongs
to the same family as Rif. The activity of DEM30355B1/B2 was also tested against B.subtilis
RNAP using the same experimental set up. Again, inhibition of transcription of the full-length
product was observed in the presence of both compounds (Figure 7.2 b Lanes 6 to 11), similar
to the positive control, Rif.
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The activity of the two compounds was also tested against the single subunit RNAP from T7
RNAP. Lanes 2 to 7 show the effect of transcription in the presence of both DEM30355 B1
and B2. In this case, no inhibition of transcription of the full-length product was observed in
the presence of either compound B1 or B2 (Figure 7.2 c, Lanes2 to 7). Indicating that neither
compound has an effect on single subunit RNAPs.
B1           B2   RIF       B1     B2   
1    2    3   4    5    6   7 
E. coli                             B. subtilis T7 RNAP
RIF        B1          B2   
1  2   3  4  5   6  7  8  9  10  11
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(a)                                            (b)                                              (c)
Figure 7.2: Transcription in vitro carried out by E. coli, B. subtilis and single subunit T7 RNAP.
a) Inhibition of transcription initiated by wt E.coli RNAP in the presence of decreasing amounts
of Rifampicin (Lanes 3-5, 100 10 and 1 µg/mL respectively), DEM30355-B1 (Lanes 6-8) and
DEM30355-B2 (Lanes 9-11). [32 P]-RNA products were separated, on 20% PAGE-8M urea gel.
In lanes 1-2, DMSO and H2O respectively were used as controls. b) inhibition of transcription
with B. subtilis RNAP. The protocol and the concentration of the compounds was the same as in
a). H2O and DMSO were used as controls (Lanes 1-2 respectively). c) Transcription initiation
carried out by T7 RNAP. A short-T7A1 promoter was used, and each reaction was incubated
for 5 min at 37 °C . H2O was used as a control (Lane 1), the same amount of DEM30355- B1
and B2 as used in a) and b) was used. [32 P]-RNA products were separated on a 23% PAGE-8M
urea gel.
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7.2.2 DEM30355 B1 and B2 do not induce inhibition by preventing the
binding of RNAP to the DNA.
The results obtained above indicate that both B1 and B2 inhibit synthesis of the full-length
transcript products by both B.subtilis and E. coli RNAPs. From this analysis, however, it is not
known at which stage of transcription B1 and B2 exert their effects. Rifampicin, the compound
to which DEM30355 B1/B2 was hypothesised to be similar to, inhibits RNAP during initiation.
We therefore investigated whether DEM30355 B1/B2 also inhibit the RNAP in a similar way.
To study more thoroughly how DEM303055 B1/B2 inhibits transcription, an electrophoretic
mobility shift assay (EMSA, band shift assay) was performed to discover if this inhibition oc-
curs during the binding of the RNAP to the DNA. The compounds were tested against the
multi-subunit RNAP from E.coli (Figure 7.3). RNAP was mixed with DEM3055/B1 or B2 in
the presence of a short DNA fragment radiolabelled at 5’ end. DNA alone was used as a con-
trol (Figure 7.3 lanes 1-6); the compounds were added into the reactions either before or after
open complex formation (lanes 4-5 9-10). Gel analysis revealed that neither DEM30355 com-
pound inhibit the formation of RNAP/DNA initial complex. The results revealed that neither
DEM30355 B1 or B2 prevent RNAP binding to the DNA template (Figure7.3).
7.2.3 Inhibitory activity of DEM30355/B1 and B2 against mutated RNAP
As observed in the previous section, DEM30355 B1 and B2 do not destroy the initial complex
formed between RNAP and the DNA template, and allow the production of the abortive prod-
ucts but not the full length transcripts. The two compounds belong to the same family as Rif.
To further characterise the mode of action of DEM30355 B1 and B2 on RNAP, and to possi-
bly identify differences in activity compared to Rif, we decided to test their activity against a
collection of mutated RNAPs that are known to be insensitive to Rifampicin.
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Figure 7.3: Electrophoretic mobility shift assay (EMSA) in of E.coli RNAP in presence of
DEM30355 B1 and B2. [Left] experimental scheme. b= DEM3055 B1 or B2 added before RPo
formation a= DEM3055 B1 or B2 added after RPo formation. [Right] EMSA of the complex
assembled with wt E.coli RNAP and γ[32 ]-radiolabelled short T7A1 promoter fragment formed
in the presence or absence of DEM30355 B1 and B2. Complexes were resolved in native 6%
PAGE. The position of RNAP/DNA complex and not-bound DNA (free DNA) are shown.
7.2.3.1 RNAPs with mutations in the rpoB gene confer Rifampicin resistance.
The occurrence of resistance to Rifampicin was reported shortly after its introduction into
medical practice in 1967 (Alifano et al., 2015). In order to identify the mode of action of
DEM30355/B1 and B2, a diverse range of Rif-resistant RNA polymerases (RifR ) were gener-
ated and the activity of these polymerases was tested in vitro. Known mutations were selected
from the literature (see Table 7.1) and introduced into the pETLrpoB plasmid containing rpoB
gene encoding the β subunit. These mutations where introduced in a portion of the gene known
as the Rifampicin resistance determining region (RRDR) where the 95% of the mutations that
confer resistance to Rifampicin are mainly found (Ramaswamy and Musser, 1998). Based on
research in to the most common mutations present in the rpoB gene of M. tuberculosis, nine
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different mutations in the RNAPs were selected. The following table summarises all the mu-
tations in the rpoB gene used in this chapter, chosen based on the frequently in which they are
found in clinical isolates from patients.
Table 7.1: rpoB mutations
E.coli References Change M. tuberculosis
position
1 D516V (Ovchinnikov et al., 1981)
(Artsimovitch et al., 2005)
(GAC - GTC) 435
2 S531L (Vattanaviboon et al., 1994) (TCC - TTG) 450
3 H526P (Severinov et al., 1993)
(Campbell et al., 2005)
(CAC - CCG) 445
4 H526Y (Tavormina et al., 1996)
(Jin and Gross, 1988)
(CAC - TAC) 445
5 I572F (Jin and Gross, 1988)
(Campbell et al., 2005)
(ATC - TTC) 491
6 Q513L (Jin and Gross, 1988) (CAG - CTG) 432
7 D516Y (Vattanaviboon et al., 1994) (GAC - TAT) 435
8 H526R (Severinov et al., 1993) (CAC - CGC) 445
9 I572F/H526Y (Tavormina et al., 1996) 491/445
7.2.3.2 Rifampicin resistant Mutants: β D516, H526 and S531
Based on the mutations most frequently noticed in clinical isolates, we first focus on the three
most commonly found: D516V, H526Y, and S531L. Pymol software was used to model the wt
holoRNAP–rifampin complex (PDB : 4KMU) (Molodtsov et al., 2013) (Figure ??).
βD516
Asp516 is located in the centre of the Rif pocket, and interacts with the Rifamycin ansa moiety
through van der Waals contacts. The substitution mutation D516V (aspartic acid to valine) was
first mapped by Ovchinnikov et al. (1983), and is one of the three more common mutations
found in M. tuberculosis RNAP. By modifying this specific amino acid to a valine residue
causes an alteration from a negatively charged amino acid, aspartic acid, into a hydrophobic
amino acid, valine, achieved through replacing the codon GAC with GTC. A second mutation
in the β subunit is often found at the same position, D516Y, that consists of a replacement of
the aspartic acid with the tyrosine residue by mutating the codon GAC to TAT codon.
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As can be seen in Figure 7.4, the mutation D516V, clearly causes internal changes in the peptide
that do not permit the formation of any bonds between RNAP and Rif. Replacing the aspartic
acid with tyrosine (D516Y), on the other hand, does not permit the binding of Rif in the pocket
due to the loss of the negatively charged asp.
D516                                   D516V                                  D516Y
Figure 7.4: Mutations in position 516. [Left] the wt representation with in red the amino acid
implicated, [Center] a Val substitution instead of a Asp, [Right] the substitution with Tyr (PDB
accession number 4KMU. Modelled with Pymol).
βS531L
The amino acid Ser531 encoded in rpoB gene is another one of the three main mutations present
in approximately 75% of the altered clinical strains. The mutation is caused by a substitution of
the polar amino acid serine with a hydrophobic leucine by mutation of the codon TCC to TTG.
In wt RNAP, serine forms strong hydrogen bonds with the naphtol ring of Rif (visible in Figure
7.5), specifically with the O2 residue. Replacing serine with an hydrophobic residue prevents
binding of Rif, and therefore allows RNAP to continue transcription even in the presence of the
drug.
βH526
The third mutation we constructed is located at position 526 and is caused by replacement of an
histidine residue with a tyrosine. This mutation is of particular interest as it was found that the
H526Y substitution results in a high level of Rif-resistance and little or no loss of fitness of the
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S531                                                     S531L
Figure 7.5: Mutations in position 516. [Left] wt structure. [Right] is shown the Leu mutation
and the hydrogen bound is lost when the Ser is mutated. (PDB accession number 4KMU.
Modelled with Pymol)
RNAP (Alifano et al., 2015).
The H526Y mutation consist a C to T transition in the first nucleotide of the CAC codon (codon
CAC to TAC). Histidine has a positively charged imidazole functional group whilst tyrosine is
an aromatic amino acid. Initially, His-526 of the wt E. coli forms a hydrogen bond with an
oxygen molecule in the Rifampicin ansa bridge. Substitution with a tyrosine residue at this
location creates hydrogen bonds with Q513 and D516. As a consequence, there is a steric clash
with the ansa bridge blocking Rif binding. The strong effect of this substitution in conferring
resistance to inhibition with Rif is well documented in the literature (Alifano et al., 2015) and
has also been observed during in vitro transcription assays carried out as part of this project.
As well as the above-mentioned mutations, two more substitutions were created at the same
position. The histidine residue was replaced with either proline (H526P, CAC to CCG) or
arginine (H526R, CAC to CGC) resulting in RNAP enzymes containing one of three different
amino acids at the same position for comparison (wt H526,H526P and H526R). These mutations
prevent the formation of a hydrogen bond between RNAP and Rif allowing transcription to
proceed in the presence of the drug. Although the histidine was substitute with an arginine
(which has a longer side chain and an overall positive charge) the hydrogen bond, fundamental
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for the binding of RNAP by Rif, was not formed.
H526                                    H526Y 
H526R                                   H526P 
Figure 7.6: Mutations in position 526. [Top left] wt position, in yellow in shown the involved
aminoacid. H526Y, H526R and H526P are the substitutions with Tyr, Arg and Pro respectively.
(PDB accession number 4KMU. Modelled with Pymol)
βI572F and βQ513L
All of the mutations created so far are located in the Rifampicin -resistance-determining region
(RRDR), where 96% of all the mutation are found. In contrast the isoleucine 572 residue
is located in the wall of the Rifampicin binding pocket (Siu et al., 2011), outside the RRDR
region, and creates van der Waals bound with Rif, which can be destroyed by changing the
methyl group to a benzyl side. Modelling by Pymol software reveals that substitution of the
isoleucine residue with phenylalanine (codon ATC to TTC) introduces a steric clash with Rif
conferring resistance of the RNAP (Figure 7.7)
The Q513L mutation consists an A-T transition in the second nucleotide of the CAG codon
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(CAG to CTG) within the rpoB gene and was discovered in 1988. The amino acid 513 was
chosen as a target for a substitution mutation due to its interaction with the napthol ring of Rif.
By introducing a leucine amino acid in this position, the interaction with Rif was lost (Figure
7.7).
I572 I572F
Q513                                             Q513L
Figure 7.7: Mutations in position 572 and 513. [Top left] wt position in 572 and in pink in
shown the involved amino acid mutated in Phe. [Botton Left] in light blue is shown the wt
amico acid Gln mutated in Leu.(PDB accession number 4KMU. Modelled with Pymol)
7.2.4 RNAPs with mutations in the rpoC gene
As well as the mutations that confer resistance to Rif, other mutated RNAPs were tested using
both DEM30355/B1 and B2 compounds. In particular, we tested the RNAP belonging to the
Prof. Zenkin lab that contains a single substitution in the evolutionarily conserved segment
of the β’ subunit of a a serine to phenylalanine at position 793. This single mutation gives
rise to resistance of RNAP to both Streptolydigin (Stl) and MicrocinJ25. Stl interacts with
RNAP in transcription elongation complexes and inhibits growth of the nascent RNA chains
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during transcription initiation and elongation by stabilizing the inactive intermediate state and
by blocking structural isomerization of RNAP (Zorov et al., 2014). MccJ25 on the other hand
blocks transcription by preventing the entrance of the NTP into the active center of the RNAP,
at it obstructs the secondary channel and stopping the transcription reaction (Adelman et al.,
2004). We used this mutation to test if DEM30355 has a different mode of action compared to
with the previous Rif resistant RNAPs listed (Table 6.1).
7.2.5 DEM30355 B1/B2 inhibits RNA synthesis at the T7A1 promoter
All the mutated RNAPs enzyme described above were constructed , purified and tested in vitro
using a transcription initiation assay. The concentration of each RNAP was determined and 0.3
pmol of each RNAPr was used for each reaction. To determine the possibility of any inhibition
during transcription initiation, each RNAP was incubated with σ70 (15 pmol), and DNA con-
taining the T7A1 promoter (0.2 pmol). DEM30355B1 and B2 were added after the formation
of RPo, and the reactions were kept for 10 min at 37°C in presence of all four NTPs (ATP,
CTP, GTP 20 µM, and UTP 5µM) along with α32P-UTP. The reactions were stopped with the
addition of an equal volume of transcription stop buffer containing formamide and resolved on
a 20 % PAGE gel and analyzed using ImageQuant software (Table 7.2).
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In these assays we monitored the production of the full length transcripts (Run-off and Termi-
nator) and the abortive transcripts. DEM30355-B1 and DEM30355-B2 showed distinct mech-
anisms of action. DEM30355-B1 inhibits the Run-off/Terminator production of the RNAPs
mutants D516V, S531L, I572F, Q513L, D516Y, I572F/H526Y and S793F (Table 7.2). Syn-
thesis of only the full length transcripts was inhibited. Production of the small products was
unaffected. A more diverse effect was observed for DEM30355B2 as this compound did not in-
hibit RNAP with mutations D516V or Q513L. To better understand the mode of action of these
two compounds during synthesis of the abortive transcripts, an abortive transcription assay was
carried out. The same protocol for standard transcription previously described was carried out
but in presence of only one nucleotide instead of all four. The transcription-primer used was
CpA (or CpApUpC) with only α32P-UTP (or α32P-GTP) added. Each reaction was incubated
for 5 min at 37 °C with or without compounds (see Material and Methods, section 3.2). The
final product of this reaction is the small trinucleotide RNA, CpApU* or CpApUpCpG* which
is analysed by PAGE and quantified by ImageQuant software (Figure 7.8)
The results show that Rif does not alter the production of the CpApU product in presence of
wt E.coli RNAP at a final concentration of 100, 10, 1 µg/ml, in accordance with the mode of
action of Rif. D516V was used as the mutated RNAP, and, as expected, in presence of Rif
no inhibition of transcription initiation occurred (Figure7.7). DEM30355 B1 and B2 produced
the same results as Rif in the presence of wt E. coli RNAP but reduced the amount of abortive
transcripts produced by the D516V RNAP (Figure 7.7left panel).
The transcription primer CpApUpC, was also used as it is known that in the presence of Rif,
abortive products are not produced by wt RNAP (Figure 7.7 panel). RIf also inhibited the
production of abortive products by the mutant RNAP at hight concentration due to decreased
sensitivity of this mutant to Rif. DEM30355 B1 and B2 showed the same pattern of inhibition as
Rif against the wtn RNAP. The mutant RNAP D516 was more sensitive to both DEM30355B1
and B2 than Rif (Figure 7.8).
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Figure 7.8: Abortive transcription assays in presence of DEM30355B B1 and B2 with two
different transcription primers, Cpa [Left panel] and CpApUpC [Right panel]. Two different
polymerase were used, wt E.coli RNAP and D516 E.coli RNAPr.
7.3 Discussion and conclusion
The compound DEM30355 produced by the Amycolatopsis strain was purified in the DemurisTM
lab. The two compounds are both members of the Ansamycin family and B2 is formed as a
product of the degradation of B1. Both B1 and B2 are also structurally similar to the antibiotic
Rif. Based on these similarities, it would be expected that both B1 and B2 exhibit similar effects
during transcription in comparison to each other as well as to Rif. This indeed proved to be the
case when they were tested in vitro transcription elongation assays against wt E. coli, B subtilis
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and T7 RNAP. All three compounds inhibited the production of the full length transcripts but
still produced the abortive transcripts.
Based on these observations, we hypothesised that B1 and B2 bind to the same place on the
RNAP as Rif i.e. in the Rif pocket. To test this hypothesis, a series of mutated RNAPs were
designed that contained single amino acid substitution mutations in the region of the RNAP
that interacts with Rif and therefore decreases the sensitivity of the RNAP to inhibition by Rif.
These mutations were based on those found in the RNAP enzymes from clinical isolates of M.
tuberculosis. When the mutated RNAPs were used in an in vitro transcription assay and the
inhibitory effect of DEM30355 B1/B2 on abortive initiation compared to that of Rif, B1 and B2
exhibited different effects on the RNAP compared to Rif and also to each other. This suggests
that although B2 is a degradation product of B1 and as such is structurally very similar, the
slight difference between them leads to a variation in the mechanisms of action.
Based on the in vitro assays alone it is not possible to determine the exact mechanism of action
of either B1 or B2, however, these compounds are potentially novel as they differ from Rif both
structurally and in the way they inhibit RNAP. In order to better understand the interactions
between B1/B2 and RNAP, Further analysis is required, for instance co-crystallisation of each
compound with the RNAPr.
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Chapter 8
Discussion and Conclusion
The increasing amount of drug resistant organisms is producing a human health crisis, and we
are in fact exacerbating the emergence of these new and resistant pathogens. At the beginning,
and throughout this project, we have had the opportunity to screen isolates directly taken from
an actinomycetes collection belonging to DemurisTM. These strains were initially screened by
DemurisTM in a whole cell-based preliminary screening using E. coli, S. aureus and B. subtilis,
and only the strain with the ability to produce secondary metabolites with an inhibitory effect
against live bacteria were short-listed.
A panel of reporter strains were used prior to biochemical techniques, to reveal the preliminary
MOA, and those selected were extracted from agar plates. Samples then underwent Organic
extraction and Solid Phase extractions before they were analysed in-vitro in our lab.
Following analysis, viable samples were put through a fermentation process during which they
produced active compounds. These compounds were extracted and purified using different
chromatography techniques including the use of High-Performance Liquid Chromatography
(HPLC), organic extraction, Solid Phase Extraction (SPE), and Thin Layer Chromatography
(TLC). Mass spectrometry and NMR were then used to determine the mass and structure of the
molecule, after the in-vitro activity of these pure compounds were confirmed
More than 100 compounds were tested in our lab, and the three most significant are described
in this thesis. The three compounds are:
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1. DEM31376
2. DEM10430
3. DEM30355B
DEM31376: corresponds to Madurastatin C1, a compound produced by Actinomadura sp., has
not been well studied for inhibition against any RNAP. There are few known papers about this
compound, and until now, only the isolation and structural characteristics have been well studied
(Harada et al., 2004). During experimentation, we found a co-production of another compound
from the same strain, known as GE23077 compound. The mode of action found during our
assay, for this last compound, corresponds to recently published data. Most interesting is the
structure of Madurastatin C1 but again, this has not been well studied in any in vitro RNAP
assays - and it is for this reason that our collaborators in the chemical lab, are trying to isolate
and separate Madurastatin C1 from GE23077.
DEM10430: corresponds to the Echinomycin compound, and was found to have peculiarly in-
tercalation characteristics into the DNA. DEM10430 binds specifically at CG sequences, and
we found that RNAP is able to stop 1 bp upstream to the compound. The nature of the binding
is very strong between the compound and the DNA, and in fact RNAP is not able to dissociate
the compound when the binding has already occurred.
DEM30355B: produced from the Amycolatopsis strain, was found to exist in two different
isoforms: B1 and B2. By using X-ray diffraction and NMR, it was possible to elucidate the
structure. B1 was found to be related, and b2 was found to be identical to Kanglemicin A - an
ansamycin compound originally isolated by Wang et al (1988). This compound is similar to
the structure of Rif and from our results we can assume that they have the same RIF pocket for
binding the RNAP, but, the mode of action does not coincide with the Rif. Crystallization with
each RNAPr is needed to better understand all of the bonds within the Rif pocket.
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Chapter 9
Appendix
Abortive assay 
1      2 3 4 1        2 3 4
Free 
NTPs
Free
NTPs
CpApU*
CpApUpCpG*
CpA + U* CpApUpC + G*
Rifampicin (Rif)
Formula C43H58N4O12 
Molar mass: 822.94 g/mol 
Figure 1: [Top panel] Rif Structure
[Bottom panel] Abortive transcription in presence of both transcription primer CpA and
CpApUpG respectively. Lane 1 DMSO as control.
Rif was used at 100 µg/mL,10 µg/mL and 1 µg/mL. (Lanes 2-3-4) Each reaction was carried out
using CpA dinucleotide (or CpApUpG) primer and an appropriate radiolabel NTP was added
with a DNA template containing the T7A1 promoter. The products were resolved on 33%
denaturating polyacrylamide gel.
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1   2   3   4
T7 RNAP B. Subtilis RNAP 
1  2  3  4
Run Off
Terminator
E. Coli RNAP   
Abortive 
products
Free
NTPs
Abortive 
products Free 
NTPs
Abortive 
Products
Transcription from a promoter
1 2 3  4
Rifampicin (Rif)
Figure 2:
a) Transcription assay with E.coli RNAP. RNAP was incubated with T7A1 promoter DNA. Rif
as added before RPo formation, in decreasing amounts (100 µg/ml; 10 µg/ml and 1 µg/ml, Lanes
2-3-4 respectively). Lane 1, DMSO control The reactions proceeded in the presence of all four
NTPs (25 µM ATP, GTP, CTP, 5 µM UTP and a[32 P]-UTP) and were incubated for 10 min at
37 °C
b) Transcription assay with T7 RNAP. RNAP was incubated with a short T7A1 promoter DNA.
Rif was added after RPo formation, in decreasing amount (as above). The reactions proceed in
the presence of all four NTPs (25 µM ATP, GTP, CTP, 5 µM UTP and a[32 P]-UTP) and were
incubated for 5 min at 37 °C .
c) Transcription assay with B. subtilis. RNAP was incubated with a T7A1 promoter DNA. Rif
was added after RPo formation, in decreasing amount (as above). The reactions proceed in
the presence of all four NTPs (25 µM ATP, GTP, CTP, 5 µM UTP and a[32 P]-UTP) and were
incubated for 10 min at 37 °C
All reactions were resolved in 20 Roff= run off (157nt), T=terminator (100 nt).
CHAPTER 9. APPENDIX 91
RIF
RNAP
DNA
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EMSA
Free DNA
RNAP:DNA
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Run off
Terminator
2 3 4 
EC 11
H
2
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R
if
Rifampicin (Rif)
Figure 3:
[Left panel] Electrophoretic mobility shift assay (EMSA) of Rif/RNAP complex. Rif was
added before and after (b and a, 1st and 2nd Lanes respectively) Rpo formation. 3rd Lane is
shown Rif (100 µg/ mL) with DNA into the reaction. 4st Lane RNAp/DNA complex without
compound and 5st only DNA is pesent. Each sample was loaded in 4reaction containing 25
µg/mL of heparin. Radioactive bands were analysed using ImageQuant software.
[Right panel] Elongation in vitro. EC11 was incubated in presence of NTPs for 10 min at 37
°C before being stopped by addition of an equal volume of stop buffer containing formamide.
The products were separate on 23H2O and DMSO were used as compound. Rif (100 µg/ mL)
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